Integrative Genome-Wide Association Studies of COVID-19 Susceptibility and Hospitalization Reveal Risk Loci for Long COVID

Zhongshan Cheng[1*]

1. Center for Applied Bioinformatics, St. Jude Children's Research Hospital, 262 Danny Thomas Hospital, Memphis, TN 38105, USA

*Corresponding authors:

Zhongshan Cheng: Senior Bioinformatics Research Scientist, Center for applied bioinformatics, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, United States; email: cheng.zhong.shan@gmail.com

Keywords: COVID-19, SARS-CoV2, Long COVID, GWAS, TWAS, Hospitalization, Susceptibility

Abstract

Long COVID presents a significant public health challenge, characterized by over 200 reported symptoms
spanning multiple organ systems, and genome-wide association studies (GWAS) have been hindered by the
disorder's symptom heterogeneity and the limited power of available datasets. To overcome the challenges
of limited sample size or heterogeneity of long COVID cohorts, a proxy-based, hypothesis-generating
strategy is conducted to prioritize candidate risk loci that may contribute to long COVID by analyzing
GWAS summary statistics for COVID-19 susceptibility and hospitalization, as well as long COVID from
the COVID-19 Host Genetics Initiative (HGI, Release 7), resulting in 62 candidate loci represented by
independent single nucleotide polymorphisms (SNPs). These SNPs are categorized into three groups based
on their association with acute-phase COVID-19: (1) severe COVID-19-specific SNPs, such as SNPs
mapped to two well-known loci involved in SARS-CoV2 entry (*ACE2* [rs190509934] and *TMPRSS2*
[rs12329760]), as well as variants of *DPP9* (rs7251000), *FOXP4* (rs12660421) and *HLA-DQA1*
(rs17219281), exhibiting associations with severe COVID-19 but displaying weaker signals in non-
hospitalized COVID-19 cases; (2) SNPs associated with both severe and mild COVID-19, including the
SNP close to *ABO* (rs505922); and (3) non-hospitalization-specific SNPs, such as variants in *KCTD16*
(rs62401842) and *WASF3* (rs56143829), highlighting genetic contributors specific to mild COVID-19 cases.
These candidate SNPs are investigated with recently published long COVID GWAS data from HGI,
revealing most of these candidate SNPs display much weaker association with long COVID. Further
transcriptome-wide   association   studies   (TWASs)   for   GWASs   of   COVID-19
hospitalization/susceptibility/long COVID across 48 GTEx tissues demonstrate that genes adjacent to these
candidate SNPs (43 out of 62 SNPs) exhibits relatively weaker association signals in long COVID across
heart, brain, and muscle-related tissues, particular for notable TWAS hits, *DPP9* (rs7251000), *CCR1*
(rs17078348), and *THBS3* (rs41264915) that display much weaker association in long COVID compared
to acute-phase COVID-19. Phenome-wide TWASs also link *HLA-DQA1* (rs17219281), *HLA-A* (rs9260038),
and *HLA-C* (rs1634761), *GSDMB* (rs9916158) and *FOXP4* (rs12660421) with other phenotypes closely
relevant to long COVID. These results provide new insights to long COVID by leveraging acute-phase
COVID-19.

Introduction

Long COVID remains a critical and complex public health issue, with a diverse array of over 200 reported symptoms affecting multiple organ systems[1]. These symptoms, which include fatigue, cognitive impairment, respiratory issues, and cardiovascular problems, can persist well beyond the acute phase of COVID-19 infection, revealing a unique challenge for researchers to identify genetic risk factors using genome-wide association studies (GWAS), as the wide variation in symptom clusters may arise from different biological mechanisms of long COVID and require extensive sample sizes to detect meaningful associations. To address this complexity, long COVID GWAS requires not only large and diverse patient datasets but also refined approaches to phenotype classification and statistical analyses.

Among the most significant efforts to understand the genetic basis of long COVID is the large GWAS from the COVID-19 Host Genetic Initiatives (HGI) conducted by Lama et al.[2], which analyzed approximately 3,500 long COVID cases but only identified a single gene, *FOXP4*, on chromosome 17, reaching genome-wide significance for association with long COVID. *FOXP4* variants were found to be strongly associated with both long COVID and severe COVID-19, in line with a shared genetic predisposition that may drive both conditions[3]. However, a stronger association of *FOXP4* with severe COVID-19 suggests that *FOXP4* may contribute primarily to risk factors influencing severe acute COVID-19 cases that later progress to long COVID[3]. Given that long COVID can also follow mild COVID-19, additional genetic contributors specifically associated with mild cases likely remain undiscovered.

Another long COVID GWAS conducted by Taylor et al.[4] provided further insights into genetic factors specific to a subtype of long COVID by investigating genetic overlap between long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), a condition with substantial symptom overlap, including chronic fatigue and cognitive impairments. However, their GWAS faced limitations due to its relatively small sample size (n < 1,000 long COVID cases) and only reported SNPs derived by network analysis without identifying any SNPs that reached genome-wide significance for long COVID, emphasizing the need for larger, more statistically robust studies.

More recently, a multi-ancestry GWAS was conducted by Chaudhary et al.[5], which expanded the scope of long COVID GWAS by including participants from diverse ancestral backgrounds. Notably, several immune-related loci, such as *ABO*, *BPTF*, and *HLA-DQA1*, were reported to be linked with chronic fatigue syndrome (CFS), fibromyalgia, and depression, suggesting potential immune dysregulation in long COVID. Despite this, this multi-ancestry long COVID GWAS still has limited sample size in non-European samples,

leading to the lack of sufficient power to detect associations for less common symptom clusters or subtle

genetic variants.

Compared to the limited long COVID GWAS hits reported by Lama et al. and others, large-scale GWAS

from the HGI have robustly identified genetic variants associated with COVID-19 susceptibility (infection

vs. population) and hospitalization (hospitalized vs. non-hospitalized or general population)[6]. Since both

COVID-19 acute severity and susceptibility are known risk factors for long COVID[7], we hypothesize that

genetic variants associated with these acute-phase COVID-19 may also influence the risk of developing

long COVID given the strong phenotype-wide correlation between long COVID and acute-phase COVID-

19[8]. To explore the rich data of acute-phase COVID-19 and search for potential long COVID risk loci, we

performed an integrative analysis using COVID-19 susceptibility and hospitalization GWAS summary

statistics as proxy phenotypes along with published long COVID GWAS from HGI. We first classified

associated SNPs by their specificity/commonality to COVID-19 hospitalization or non-hospitalization and

prioritized candidates SNPs for further evaluation of genes adjacent to them in published long COVID

GWASs. Additionally, genes close to these candidate SNPs were evaluated in transcriptome-wide

association studies (TWAS) of acute-phase COVID-19 and long COVID GWASs, as well as in phenome-

wide association studies (PheWAS). Our objective was not to identify long COVID loci directly but to

generate a set of candidate SNPs/genes that may contribute to both acute and chronic COVID-19 outcomes.

This approach complements ongoing efforts in long COVID research and offers a framework for

prioritizing long COVID loci to be validated in future studies.

Methods

Genome-wide Screening for SNPs Associated with COVID-19 Susceptibility, Hospitalization or Non-

Hospitalization

To screen for unique/common genetic elements predisposing to COVID-19 susceptibility, hospitalization

and non-hospitalization, COVID-19 GWAS datasets with large sample sizes were downloaded from the

HGI (release 7), including HGI-C2 (COVID-19 [n=159,840] vs. the general population [n=2,782,977]),

HGI-B1 (hospitalized [n=16,512] vs. non-hospitalized COVID-19 [n=71,321]), and HGI-B2 (hospitalized

COVID-19 [n=44,986] vs. the general population [n=2,356,386]). The latter two GWASs, HGI-B1 and

HGI-B2, were compared for effect sizes of each SNP genome-wide using differential z-score method,

resulting in a new GWAS, called HGI-B1-vs-B2, that captures SNPs displaying differential effect sizes

mainly because of the using of different controls by the two GWASs, i.e. HGI-B1 using non-hospitalized

COVID-19 as controls but HGI-B2 employing general population as controls. HGI also conducted long

COVID GWASs with 4 slightly different case-control designs that were published by Lammi et al[9] (see

supplementary Table S1), these long COVID GWASs were also downloaded but only used in evaluation of

top hits derived from the comparison of the 4 acute-phase COVID-19 GWASs. Subsequently, by comparing

these acute-phase COVID-19 GWASs, SNPs were separated into three categories, with the first categories

labeled as "Severe COVID-19-Specific SNPs," which includes SNPs associated with both SARS-CoV-2

susceptibility and COVID-19 hospitalization but tends to be more prevalent within hospitalized than in

non-hospitalized COVID-19, the second SNP category named as "SNPs Associated with Both Severe and

Mild COVID-19," which influences both hospitalized and non-hospitalized COVID-19, and the last SNP

category defined as "Mild COVID-19-Specific SNPs," which tends to be specifically associated with non-

hospitalized COVID-19.

For the 1st SNP category, "Severe COVID-19-Specific SNPs," the following selection criteria were applied,

including (a) $P \leq 0.05$ in HGI-C2, capturing SNPs linked to COVID-19 susceptibility; (b) $P > 0.05$ in the

differential GWAS of HGI-B1 vs. HGI-B2, keeping SNPs without differential effect sizes between these

comparisons; (c) $P \leq 0.05$ in HGI-B2, identifying SNPs distinguishing hospitalized COVID-19 individuals

from the general population; (d) $P \leq 0.05$ in HGI-B1, identifying SNPs that predispose individuals to

COVID-19 hospitalization rather than non-hospitalized COVID-19; (e) all SNPs required to display

consistent effect size directions across HGI-C2 and HGI-B2. Only independent SNPs passing the $P < 1 \times 10^{-7}$

in any of the three GWASs (HGI-B1, HGI-B2, or HGI-C2) were selected as candidate SNPs.

In terms of the 2nd SNP category, "SNPs Associated with Both Severe and Mild COVID-19," representing

SNPs not significant between hospitalized and non-hospitalized cases but exhibiting associations with

SARS-CoV-2 susceptibility and COVID-19 hospitalization when compared to the general population. The

selection criteria for this group were performed as follows: (a) $P \leq 0.05$ in HGI-C2, identifying COVID-19

susceptibility-related SNPs; (b) $P \leq 0.05$ in the differential GWAS of HGI-B1 vs. HGI-B2, capturing SNPs

with distinct effects in the two GWASs; (b) $P \leq 0.05$ in HGI-B2, identifying SNPs associated with COVID-

19 hospitalization; (c) $P > 0.05$ in HGI-B1, capturing SNPs with non-significant difference in effect sizes

between severe and mild COVID-19; (e) all prioritized SNPs need to fulfill consistent effect size directions

across HGI-C2 and HGI-B2. Similarly, only independent SNPs passing the $P < 1 \times 10^{-7}$ in any of these three

GWASs (HGI-B1, HGI-B2, or HGI-C2) were selected as candidate SNPs.

The last SNP category is designated as "Mild COVID-19-Specific SNPs." The rationale is that current

COVID-19 GWAS analyses from the HGI are predominantly biased toward acute-phase, hospitalized cases,

potentially overlooking SNPs associated with mild COVID-19 that emerge specifically in non-hospitalized

individuals who might later develop chronic COVID[7].

To address this gap, SNPs in the 3rd SNP category were obtained by using the following criteria: (a) $P \leq 0.05$

in the differential GWAS between HGI-B1 and HGI-B2, retaining SNPs with differential association signals

between these datasets; (b) $P>0.05$ in the GWAS comparing hospitalized cases with the general population

(HGI-B2), which excludes SNPs associated with COVID-19 hospitalization; (c) $P \leq 0.05$ in the GWAS

comparing hospitalized cases with non-hospitalized cases (HGI-B1), which captures SNPs significantly

differing these two groups, obtaining SNPs specifically associated with mild COVID-19. To further refine

the selection, independent SNPs with minor allele frequency (MAF) less than 0.01 in the largest cohort

HGI-C2 and met a suggestive significance threshold ($P<1\times10^{-5}$) were prioritized. These SNPs were also

ensured that no other genome-wide significant SNPs to it within a 500-kb window in either HGI-B2 or

HGI-C2. The use of a relaxed significance threshold and stricter MAF filter aimed to account for the higher

heterogeneity among non-hospitalized cases in HGI-B1 and the inherent bias of HGI GWASs toward

identifying SNPs associated with hospitalization. This approach enables the identification of SNPs that

might represent unique genetic contributors to non-hospitalized COVID-19.

Finally, all these candidate SNPs obtained using the above criteria were subjected to evaluation among

acute-phase COVID-19 GWASs of susceptibility and hospitalization from HGI, sex-stratification COVID-

19 hospitalization GWASs from UK Biobank, and long COVID GWASs from HGI.

Comparing Two GWASs Using Differential Z-Score Method

To assess differences in effect sizes of SNPs between two GWASs, such as one GWAS comparing

hospitalized cases with non-hospitalized cases (HGI-B1) and the other GWAS comparing hospitalized cases

with the general population (HGI-B2), or two sex-stratified COVID-19 hospitalization GWASs, differential

z-score method[10] was applied in current study. This approach quantifies the disparity in effect sizes (β) of

each SNP between two GWASs by calculating a differential z-score, which incorporates adjustments for

potential sample overlap between studies. The corresponding p-value was derived from the normalized

differential z-scores. The differential z-score is defined as:

164
$$\Delta Z - score = \frac{gwas1.\beta - gwas2.\beta}{\sqrt{(gwas1.se^2 + gwas2.se^2)}}$$

165
$$diff.zscore = Normalization(\Delta Z - score)$$

166
$$P = pnorm(-|diff.zscore|) * 2$$

Here, gwas1.β and gwas2.β represent the effect sizes for a given SNP from the two GWASs, while gwas1.se

and gwas2.se denote the corresponding standard errors. To account for genome-wide correlation in effect

sizes caused by overlapping samples, differential z-scores were normalized using the SAS procedure "proc

stdize" with the "std" method. Subsequently, differential p-values were computed based on the normalized

differential z-scores. The cumulative distribution function of the standard normal distribution ("pnorm")

was used to calculate p-values from the normalized scores.

Sex-Biased Associations with COVID-19 Hospitalization among Top Candidate SNPs

Epidemiological evidence indicates that women are more likely to experience long COVID but less likely

to develop severe COVID-19[11,12], potentially due to stronger immune responses to SARS-CoV-2 infection

in women[12]. To investigate whether these candidate SNPs exhibit sex-biased associations with COVID-19

hospitalization/non-hospitalization, we analyzed publicly available sex-stratified GWAS summary statistics

from the GRASP COVID-19 database[13] generated based on UK Biobank samples. The selected sex-

stratified COVID-19 hospitalization GWASs (cases=1,343 and controls=262,886 for females; cases=1,917

and controls=221,174 for males) includes mixed ancestry populations which are similar to the four HGI

COVID-19 GWAS datasets used in our study. We used the aforementioned differential z-score method to

compare male and female COVID-19 hospitalization GWAS results, and SNPs with differential effect sizes

between sexes for COVID-19 hospitalization were identified. Genomic inflation factors for both sex-

stratified GWASs and the sex-biased differential GWAS were also evaluated to ensure they don't have

inflation.

Evaluate the Associations of Top Candidate SNPs and Its Adjacent SNPs with Long COVID

Four HGI long COVID GWASs, including LongCOVID-N1, LongCOVID-N2, LongCOVID-W1, and

LongCOVID-W2 (see Table S1), with slightly different case and control designs were used to evaluate the

association signals of these candidate SNPs. Due to the nature of phenotypic difference between acute-

phase COVID-19 and long COVID, adjacent SNPs, located within a 1Mb-genomic window where each top

candidate SNP residing in, were screened across these long COVID GWASs, and the one with the smallest

long COVID association signals passed the significance threshold of $P<0.001$ were kept for further analyses,

such as manual evaluation with local Manhattan plots and forest plots. These loci with nominal significant

top SNPs or its adjacent SNPs passed the $P<0.001$ in any of these long COVID GWASs are treated as

potential candidate loci involved in long COVID.

Evaluation of Previously Reported Long COVID SNPs in Current Acute-Phase COVID-19 GWASs

To assess whether these prioritized candidate SNPs identified in our study overlap with or are proximal to

those reported in two independent long COVID GWASs by Taylor et al.[4] and Chaudhary et al.[5], a set of 83

SNPs derived from SNP network analyses and 3 SNPs identified via traditional GWAS methods specifically

from the two studies were created and analyzed for their association signals among the three acute-phase

GWASs from HGI.

Transcriptome-Wide Association Analysis Using S-MetaXcan

Transcriptome-wide association analysis (TWAS) was conducted using S-MetaXcan[14], which infers gene expression association with a phenotype based on its corresponding GWAS summary statistics and GTEx gene expression datasets across 48 tissues. Four COVID-19 GWAS datasets from the HGI were analyzed, including HGI-B1, HGI-B2, HGI-C2, and HGI-B1-vs-B2, alongside four long COVID GWAS datasets with subtly distinct case-control definitions from HGI[9] and an additional set of 222 GWASs from the UK Biobank (UKB) (all sample sizes of cases >5000) shared by Benneal's lab (https://www.nealelab.is/uk-biobank). Reference transcriptomic data from 48 tissues in GTEx v7[15] were utilized for gene expression imputation in the analyses.

In detail, S-MetaXcan[14] employs multivariate regression to integrate evidence across different GTEx tissues (n=48), enhancing the detection power. Default settings were applied, with the conditional number for eigenvalue set at 30 during singular value decomposition (SVD) truncation and genes on autosomal chromosomes were included in the analysis. First, TWAS results of COVID GWAS datasets (n=8, collectively referred to as COVID TWASs, covering 4 long COVID TWASs as well as 4 acute-phase COVID-19 TWASs) were evaluated for genes proximal to prioritized SNPs (±500kb to each SNP termed as tag SNP). Genes showing nominal significance ($P<0.05$) in any of these COVID TWASs across the 48 GTEx tissues were prioritized for further investigation.

Also, to expand these findings, phenome-wide association analyses were conducted for these prioritized genes. Associations were examined across a TWAS database aggregating 190 previously published TWAS results covering a broad set of phenotypes[14] and 222 UKB TWASs created locally with the same settings as that of the 190 published TWASs, as well as 8 COVID related TWASs generated in this study, yielding a total of 420 TWAS datasets (see Table S2).

Statistical Analysis Software and Availability of Codes and Data

Unless otherwise specified, all analyses were performed using SAS OnDemand for Academics (freely available at https://www.sas.com/en_us/software/on-demand-for-academics.html). Local Manhattan plots for the prioritized candidate SNPs are publicly accessible at the GitHub link (https://github.com/chengzhongshan/COVID19_GWAS_Analyzer/tree/main/LongCOVID_data_and_scripts/LongCOVID_SNP_LocalManhattanPlots). SAS scripts involved in post-GWAS analyses for these acute-phase COVID-19 and long COVID GWASs are put into the same github folder. Acute-phase COVID-19 and long COVID GWASs used in our study are accessible via Google Driver

(THREEGWASs4HGICOVID19.gz:

https://drive.google.com/file/d/1nZZsxbXJROjGmBGqq84WbCtPLlZWDT3C/view?usp=sharing;

CombineLongCOVIDGWAS.gz:

https://drive.google.com/file/d/1opd3BSC5JAHoPvDZPmqPB11Ox8YTrG-X/view?usp=sharing). A

readme document explaining details of the two compressed datasets is accessible here

(https://docs.google.com/document/d/1EVA-gUZyGeiyb4GPDuliUyT044WBya_I/edit).

Results

Comparison of Three Acute-Phase COVID-19 GWASs from HGI

To search for candidate genetic SNPs commonly or specifically associated with COVID-19 hospitalization

and non-hospitalization, an integrative workflow was developed by leveraging publicly available COVID-

19 GWAS (Fig. 1). Initially, acute COVID-19 phenotypes, such as SARS-CoV-2 susceptibility, COVID-19

hospitalization, and non-hospitalization, were used to prioritize genetic variants potentially, specifically

linked to COVID-19 hospitalization or non-hospitalization, as well as associated with both of the two

COVID-19 phenotypes. The analysis utilized GWAS data from the HGI release 7, including GWASs of

hospitalized vs. non-hospitalized cases (HGI-B1), hospitalized cases vs. the general population (HGI-B2),

and SARS-CoV-2 infection vs. the general population (HGI-C2). These GWASs comprise large sample

sizes (16,512, 44,986, and 159,840 COVID-19 cases for HGI-B1, HGI-B2, and HGI-C2, respectively; Fig.

1) and exhibit minimal genomic inflation (all λs close to 1), as shown in supplementary Fig. S1, and two

loci, including *SLC6A20* and *ABO*, displayed notable genome-wide significance, which were well-

established contributors to COVID-19 susceptibility and severity[16].

Candidate SNPs Specifically Associated with Hospitalized COVID-19 or Commonly Associated with

Both Hospitalized and Non-hospitalized COVID-19

Base on the filtering strategies illustrated in the workflow shown in Fig. 1, two SNP groups were prioritized

first, including "Severe COVID-19-Specific SNPs" (n=27) and "SNPs Associated with Both Severe and

Mild COVID-19" (n=15), resulting in 42 independent SNPs (Table 1 and Fig. 2). It is necessary to

emphasize that these two SNP categories are designated to capture SNPs either linked predominantly to

SARS-CoV-2 susceptibility and COVID-19 hospitalization coupled with higher prevalence in hospitalized

cases than in non-hospitalized cases, or associated with both severe and mild COVID-19 that demonstrate

consistent associations with SARS-CoV-2 susceptibility and hospitalization along with no frequency

difference between hospitalized and non-hospitalized cases. Among these 42 independent SNPs included

in the two SNP categories, all SNPs passed the conventional genome-wide significance threshold ($P<5 \times 10^{-8}$

^{8}) in at least one HGI COVID-19 GWAS, with the exception of two SNPs, rs150345524 (*SF3B1*, $P=5.6 \times 10^{-}$

[8] in HGI-B2) and rs11766643 (*SLC22A5*, P=7.5x10^{-8} in HGI-C2), that are suggestively genome-wide
significant.

To reveal biological insights, each of the above 42 COVID-19-associated SNPs was linked with its
corresponding nearest gene to create a SNP-gene pair. It is necessary to note that proximity-based
assignments may overlook distal regulatory effects, and this potential issue will be further addressed in
subsequent transcriptome-wide association studies. In detail, notable SNPs along with its corresponding
nearest gene in the 1st SNP category, "Severe COVID-19-Specific SNPs," include rs10774679 (*OAS3*),
rs17169628 (*SLC22A31*), rs12329760 (*TMPRSS2*), rs12660421 (*FOXP4*), rs17078348 (*SLC6A20*),
rs190509934 (*ACE2*), rs2834164 (*IFNAR2*), rs3785884 (*MAPT*), rs7251000 (*DPP9*), and rs76608815
(*SLC5A3*), among others (Table 1), and this SNP category contains a total of 27 SNPs showing stronger
associations with severe COVID-19 than with mild cases (Fig. 2 and Fig. S2). Meanwhile, for the 2nd SNP
category, "SNPs Associated with Both Severe and Mild COVID-19", five out 15 SNP-gene pairs, including
rs2290859 (*NXPE3*), rs505922 (*ABO*), rs149533170 (*IFNA21*), rs34536443 (*TYK2*), and rs9916158
(*GSDMA/B*), demonstrates consistent associations across GWAS datasets without differential effects
between hospitalized and non-hospitalized groups (Fig. 2 and Fig. S3). Notably, *ABO* (rs505922) has been
reported as a genetic locus associated with long COVID[5]. Several other immune-related genes were found
close to other candidate SNPs, including *IFNA21* (rs149533170), *TYK2* (rs34536443), *GSDMA/B*
(rs9916158), *BCL11A* (rs1123573), *ELF5* (rs2924480), and *JAK1* (rs11208552), in accordance with the role
of immune dysregulation in both hospitalized and non-hospitalized COVID-19[17-22]. Additionally, *FUT2* is
found closely with rs492602 and encodes fucosyltransferase 2, a key enzyme in the ABO antigen synthesis
pathway, further underscores the involvement of *ABO* in COVID-19 outcomes[23]. Additionally, four genes—
TAC4[24], *NXPE3*[25], *NSF*[26], and *FOXG1*[27]—linked to neuronal functions were close to rs75432325,
rs2290859, rs1378358, and rs150497803, respectively, while three genes—*ZKSCAN1*[28], *BCL11A*, and
FOXG1—identified as transcription factors were linked to rs2897075, rs1123573, and rs150497803,
respectively.

We also evaluated sex-biased associations for these 42 candidate SNPs in the first 2 SNP categories (Fig.
S4). Due to the smaller sample sizes in the sex-stratified COVID-19 hospitalization GWASs from UK
Biobank, only 15 SNPs reached nominal significance (P<0.05) in at least one of these three GWASs,
including COVID-19 hospitalization for males and females, and differential COVID-19 hospitalization
between males and females. Of these, rs17078348 (*SLC6A20*), a well-established severe COVID-19 risk
SNP[29], showed nominal significance in both male and female cohorts of COVID-19 hospitalization. Five
SNPs displayed nominal significance exclusively in females, including rs75432325 (*TAC4*), rs505922
(*ABO*), rs12660421 (*FOXP4*), rs7251000 (*DPP9*), and rs11766643 (*TFR2*). Eight SNPs were nominally

significant only in males, including rs897075 (*ZKSCAN1*), rs117169628 (*SLC22A31*), rs7515509 (*AK5*), rs76608815 (*SLC5A3*), rs12585036 (*ATP11A*), rs5023077 (*FBRSL1*), rs10774679 (*IFNAR21*), and rs12329760 (*HLA-C*). None of the SNPs passed the stringent multiple testing correction threshold ($P<6\times10^{-4}$), and local Manhattan plots for 12 of the 42 SNPs revealed relatively weaker association signals in the sex-stratified GWAS in contrast with the stronger signals observed in HGI-B2 (Fig. S5). This reduction in signal strength likely reflects the smaller sample sizes in the sex-stratified datasets, implicating reduced statistical power to detect sex-biased associations. In summary, while the sex-biased GWAS analysis did not identify SNPs with statistically significant sex-biased associations with COVID-19 hospitalization, it highlighted 15 SNPs with nominal significance, including rs505922 (*ABO*) and rs12660421 (*FOXP4*), which have been previously implicated as risk variants for both severe COVID-19 and long COVID. These findings warrant further investigation in larger sex-stratified COVID-19 GWAS as well as long COVID GWAS.

Candidate SNPs Specifically Associated with Non-Hospitalized COVID-19

To identify potential candidate SNPs specific to non-hospitalized COVID-19 cases, we screened for SNPs that showed suggestive significant association signals in HGI-B1 (hospitalized vs. non-hospitalized, $P<1\times10^{-5}$) and HGI-B1-vs-B2 (differential GWAS between HGI-B1 and HGI-B2, $P<0.05$) but were non-significant in HGI-B2 (hospitalized vs. general population, $P>0.05$) and were not in proximity to any genome-wide significant SNPs in HGI-B2. We also only focused on top hits with MAF<0.01 in the HGI-C2 with the largest sample size compared to other COVID-19 GWASs from HGI. This selection prioritized 20 independent SNPs potentially specifically associated with mild (non-hospitalized) COVID-19 cases (Table 2; Fig. S6). All 20 SNPs showed suggestive genome-wide significant differences in effect sizes between HGI-B1 and HGI-B2 ($P<1\times10^{-5}$). Although none met the genome-wide significance threshold ($P<5\times10^{-8}$), notable findings were observed by linking these candidate SNPs with their adjacent genes. For example, rs62401842 (*KCTD16*) exhibited the strongest association in HGI-B1 ($P=8.53\times10^{-7}$), while showing no association in HGI-B2 ($P=0.38$), resulting in a significant difference between HGI-B1 and HGI-B2 ($P=3.18\times10^{-7}$). Gene *KCTD16*, encoding potassium channel tetramerization domain-containing 16[30], is highly expressed in brain tissues according to the GTEx database[15]. In addition, eight SNPs illustrated in Fig. S6 were mapped to genes with brain-related functions, including rs9799354 (*NLGN1*[4]), rs112842080 (*CPLX2*[31]), rs61858037 (*NRG3*[32]), rs61939166 (*KIF21A*[33]), rs367777 (*NAV3*[34]), rs56143829 (*WASF3*[35]), rs11454577 (*AKAP6*[36]), and rs6049828 (*SYNDIG1*[37]). Among these, *WASF3* has been implicated in mitochondrial dysfunction and may mediate exercise intolerance in myalgic encephalomyelitis/chronic fatigue syndrome[35]. Additionally, among these 20 candidate SNPs identified, only three SNPs (rs62401842 [*KCTD16*], rs9799354 [*NLGN1*], and rs112842080 [*CPLX2*]) exhibit male-

biased associations with COVID-19 hospitalization at nominal significance levels (Fig. S7). Furthermore, six candidate SNPs, including rs62401842 (*KCTD16*), rs9799354 (*NLGN1*), rs112842080 (*CPLX2*), rs56143829 (*WASF3*), rs4737438 (*PENK*), and rs6049828 (*SYNDIG1*), demonstrate sex-biased association patterns within a genomic window ranging from 500kb to 1000kb (Fig. S7). However, the limited sample sizes in sex-stratified COVID-19 GWAS preclude any candidate SNPs from achieving statistical significance after correction for multiple testing in analyses of sex-biased associations with COVID-19 hospitalization. In summary, while no genome-wide significant SNPs specific to non-hospitalized COVID-19 cases were identified, these 20 SNPs along with their adjacent genes provide suggestive evidence of association with mild COVID-19.

Association of Prioritized Candidates SNPs with Long COVID

To investigate the associations of these 62 candidates SNPs with long COVID, the published long COVID GWASs from HGI (see Table S1) were used to examine association signals of them. Notably, only one candidate SNP, rs12660421 of *FOXP4*, passed the traditional genome-wide significance threshold and significantly associated with long COVID ($P=1\times10^{-9}$) in one of four long COVID GWASs, i.e. LongCOVID-N2 GWAS (strict cases of long COVID after test-verified SARS-CoV-2 infection [n = 3,018] vs. general population controls [n = 994,582)) (Table S3, Fig. S8-S10). Among other 3 alternative long COVID GWASs with slightly different case-control designs for long COVID, including LongCOVID-W2, LongCOVID-N1, and LongCOVID-W1, rs12660421 (*FOXP4*) is also normally significantly associated with long COVID, with p-values of which equal to 9.7×10^{-7}, 4.3×10^{-3}, and 4.95×10^{-2}, respectively. However, rs12660421 (*FOXP4*) tends to be more strongly associated with COVID susceptibility ($P=7.4\times10^{-15}$) and hospitalization ($P=2.9\times10^{-10}$), supporting the SNP's association with multiple COVID-19 and long COVID phenotypes. For another 61 remaining candidate SNPs, there are 8 SNPs, comprising rs505922 (*ABO*), rs7660881 (*SLC5A3*), rs6186040 (*SFTPD*), rs2834164 (*IFNAR2*), rs1077467 (*OAS3*), rs2290859 (*NXPE3*), rs1707834 (*SLC6A20*) and rs1128420 (*CPLX2*), showing normally significance in at least one long COVID GWAS, all of which displaying much weaker association signals compared to that from acute-phase COVID-19 GWASs (Table 1 and 2, Table S3; Fig. S8-S10). Additionally, 43 out of 62 candidate SNPs, including loci *ELF5* (rs141160516), *TAC4* (rs28704677), *FUT2* (rs557806), *RAB2A* (rs113059174), *ABO* (rs544873), *GSDMA/B* (rs72832927), *HLA*-C (rs3218825), *TYK2* (rs8112028), *OAS3* (rs72487538), *KCTD16* (rs114210747), *WASF3* (rs75947067), *ATP11A* (rs3832907), *PCDH20* (rs34409482), *SLC27A6* (rs704234), and others (see Table S4), have at least one adjacent SNP displaying long COVID association signals with $P<0.001$, indicating that these loci are potentially associated with long COVID due to different genetic variants at the same locus (Table S4 and Fig. S10). The observation of much more weaker associations of these SNPs as well as its adjacent SNPs with long COVID is in line with the winners' curse,

370 since these candidate SNPs were initially selected from COVID-19 GWASs by its strong association signals

371 that are likely to be overestimated; meanwhile, it is also possible that the current long COVID GWASs are

372 biased to risk factors associated with severe COVID-19, mainly due to the overlapping samples used by

373 both long COVID cohorts and COVID-19 cohorts, leading to the observation of relatively weaker

374 association signals for these candidate SNPs in long COVID.

Evaluating Other Published Long COVID SNPs in Current COVID-19 GWASs

Previously published long COVID risk SNPs reported by Taylor et al.[4] and Chaudhary et al.[5]. were

investigated among three acute-phase COVID-19 GWASs of HGI (Table S5). The rationale is based on the

hypothesis that larger sample sizes and higher statistical power of the HGI datasets have enough power to

detect associations with traits closely related to long COVID, such as severe COVID-19 and susceptibility

to SARS-CoV-2 infection. Moreover, overlap between our prioritized long COVID SNPs and those reported

in previous studies would strengthen the hypothesis that the loci represented by these 62 candidate SNPs in

question might be implicated in long COVID pathogenesis.

Among the three SNPs (rs643434, rs2080090, and rs9273363) reported by Chaudhary et al.[5] (Fig. S11 and

Table S5), rs643434 (*ABO*) and rs2080090 (*BPTF*) demonstrated significant associations with both

COVID-19 hospitalization (HGI-B2) and susceptibility to COVID-19 (HGI-C2). In detail, rs643434 (*ABO*)

surpassed genome-wide significance thresholds in both HGI-B2 ($P= 6.7\times10^{-24}$) and HGI-C2 ($P=8.7\times10^{-85}$)

and showed non-significant association in HGI-B1 ($P=0.6$) but demonstrated significantly differential

effect sizes ($P=6\times10^{-5}$) between HGI-B1 (hospitalized vs. non-hospitalized COVID-19) and HGI-B2. This

supported its classification as a "category 2" COVID-19 SNP (associated with both severe and mild

COVID-19 phenotypes). Similarly, rs2080090 (*BPTF*) showed stronger associations in HGI-B2 ($P=1.9\times10^{-4}$)

than in HGI-C2 ($P=2.5\times10^{-2}$), with no significant association in HGI-B1. This SNP was also categorized

as a suggestive "category 2" COVID-19 SNP. In contrast, rs9273363 (*HLA-DQB1*) did not exhibit

significant associations across any of the HGI GWAS datasets analyzed (all $Ps>0.2$). Nevertheless, among

these 62 candidate SNPs, rs17219281 (*HLA-DQA1*), a "category 1" COVID-19 SNP that tends to be more

likely associated with hospitalized rather than mild COVID-19 (see Table 1), is ~50kb downstream of

rs9273363 (*HLA-DQB1*), strongly implicating that rs17219281 may be the real SNP associated with

COVID-19 hospitalization or long COVID. Taken together, the three recently published long COVID loci,

including *ABO*, *BPTF*, and *HLA-DQB1*, were completely covered by these 62 prioritized SNPs and display

association with either COVID-19 hospitalization or both COVID-19 hospitalization and non-

hospitalization.

Meanwhile, of the 80 SNPs reported by Taylor et al.[4], 12 displayed nominally significant associations in at

least one HGI GWAS dataset (Table S5 and Fig. S11). These included four SNPs associated with HGI-B2, five with HGI-B1, and seven with HGI-C2. Notably, rs4303401 (*FRMD6*) surpassed the multiple-testing correction threshold ($P<1.5\mathrm{x}10^{-4}$), representing a strong candidate SNP. Expanding the analysis to include a ±500kb genomic window around the reported SNPs identified additional suggestive genome-wide significant associations in the HGI datasets. For example, in Fig. S11, rs62401842 (proximal to *KCTD16* that shows brain-specific expression) and rs7671107 and rs1017716 (a GTEx eQTL of *ANAPC4*, which is a gene implicated in aging) emerged as promising candidates. Other noteworthy SNPs in Fig. S11 include rs12602210 (*BPTF*) and rs17412601 and rs2290859 (both mapped to *NXPE3*), which demonstrate suggestive or genome-wide significance in at least one HGI GWAS dataset. In summary, four loci, including *KCTD16*, *ANAPC4*, *BPTF*, and *NXPE3*, revealed by Taylor et al[4]. derived from SNP network analysis are independently confirmed to be nominally associated with COVID-19 related phenotypes in the current study; among them *BPTF* is a locus confirmed to be associated with long COVID by Chaudhary et al., Taylor et al., and associated with acute-phase COVID-19 in current study. Therefore, these findings underscore the potential of integrating data from diverse GWAS to elucidate the genetic architecture of acute-phase COVID-19 and long COVID to highlight candidate loci for further investigation.

Transcriptome-Wide Association Study Identifies Candidate Genes Adjacent to Prioritized SNPs for COVID-19 and Long COVID Phenotypes

To elucidate genetic mechanisms underlying these COVID-19 candidate SNPs and potential causal genes represented by these SNPs, we performed a transcriptome-wide association study (TWAS) using S-MetaXcan across 48 GTEx tissues by correlating genotype-imputed gene expression with acute-phase COVID-19 and long COVID. This approach first utilized COVID-19 GWAS summary statistics from HGI: HGI-B1, HGI-B2, HGI-C2, and HGI-B1-vs-B2. The analysis targeted 62 candidate SNPs previously prioritized and aimed to identify their adjacent genes whose expression levels may be associated with COVID-19 hospitalization or susceptibility phenotypes, and then 4 long COVID GWASs with slightly different definitions in terms of cases and controls were performed for TWAS with the same method.

We first evaluated whether these candidate SNPs and its adjacent genes were covered by TWASs of acute-phase COVID-19. Of the 62 candidate SNPs, two SNPs (rs190509934 near *ACE2* and rs9570861 near *OR7E156P*) were not included in the TWAS analysis. The former resides on chromosome X, whom S-MetaXcan excludes due to the focus of S-MetaXcan is only on autosomal genes, while the latter SNP has no protein-coding genes within a 500-kb window. Although there are 879 adjacent genes to these 62 candidate SNPs, only 776 out of them are corresponding to the remaining 60 SNPs that were tested by these COVID TWASs (Fig. S12) with detectable expression across the 48 GTEx tissues.

Next, to simplify the interpretation for TWASs, we retained only the strongest association (smallest p-value) for each gene across 48 GTEx tissues. This approach was justified by the hypothesis that specific tissues, rather than all tissues, are likely to drive the pathogenicity of COVID-19. Applying varying significance thresholds ($P<0.05$, 0.01, 0.001, 0.0001, 0.00001), the analysis revealed 422, 152, 43, 19, and 11 adjacent genes meeting these criteria in at least one of the four HGI datasets (Fig. S12, Table S6). Using a genome-wide significance threshold ($P<3.5x10^{-7}$), we found that top hits are originated exclusively from COVID-19 hospitalization and susceptibility GWAS, with no genes passed this threshold in long COVID TWASs (Fig. 3). The top three loci displayed significant associations are identified as: (1) *DPP9*, showing the strongest association signal ($P=4.6x10^{-18}$) in adipose visceral omentum tissue; (2) *CXCR6* gene cluster, which included multiple genes (*CXCR6*, *CCR3*, *CCR1*, and *LZTFL1*), displaying the most significant association ($P=1.3x10^{-10}$) in nerve tibial tissue; (3) *MUC1* gene cluster, comprising *MUC1*, *THBS3* and *FAM189B*, highlighted in multiple GTEx tissues, including lung and colon. Additional loci with suggestive TWAS significance ($P<3.5x10^{-6}$) included *FYCO1*, *SLC6A20*, and *XCR1*, specifically showing associations in HGI GWASs B1, B2, and C2 in distinct GTEx tissues.

Further determination revealed that these candidate genes proximal to 60 prioritized SNPs accounted for all top TWAS signals across the eight HGI TWASs, with the exception of *CCR5*, *EXOSC7*, *FLT1P1*, *RLN1*, *GBAP1*, *ARHGEF2*, *ZSCAN31*, *ZKSCAN3*, *PGMSP2*, *PAQR5*, and *TMIE* (Fig. S13A). Further in-depth evaluation of these outlier genes in long COVID TWASs revealed most of them lack of significance (Fig. S13B and S14), reinforcing the utility of prioritizing top candidate SNPs and their adjacent genes that might be associated with long COVID.

We then focused on the associations of these adjacent genes in long COVID TWASs across all 48 GTEx tissues using a relatively weak association threshold, i.e., the nominal significance threshold of $P<0.05$, among these top COVID-19 TWAS genes (Fig. 3, Table S7 and Fig. S14). In details, *THBS3* is the gene showing ubiquitous association with long COVID among multiple GTEx tissues, such as brain cerebellum, nerve tibial, speen, adrenal gland, colon sigmoid, testis and esophagus mucosa; *CCR3* is observed to be correlated with long COVID in the GTEx tissue heart atrial appendage; *MUC1* is predicted to be associated with long COVID in the GTEx tissue colon transverse, and *DPP9* expression associates with long COVID in both GTEx tissues colon transverse and testis. Furthermore, using a relaxed threshold ($P<0.05$), we identified additional adjacent genes associated with long COVID (Fig. 4 & Fig. S15-16). These included *OAS3* (rs10774679), *TMPRSS2* (rs12329760), *HLA-A* (rs4s9260038), *HLA-C* (rs1634761), *HLA-DQA1* (rs17219281), *WASF3* (rs65143829), *IFNAR2* (rs2834164), *SFTPD* (rs61860402), and *GSDMA/B* (rs9916158), the associations of which enriched in tissues such as heart, brain, colon, adipose, and muscle. Notably, the well-established *ABO* locus, a COVID-19 susceptibility locus, did not show significant TWAS

signals, suggesting that its effects may stem from non-expression-related mechanisms, such as genetic

mutations influencing blood types[38].

In summary, TWAS analyses identified 52 SNP-gene pairs nominally associated with long COVID across

tissues. While genes such as *DPP9, CCR1*, *THBS3*, and *MUC1* emerged as potential shared contributors to

acute and long COVID phenotypes, their tissue-specific associations suggest distinct mechanisms may

drive long COVID. These findings highlight the importance of integrative approaches in uncovering the

molecular underpinnings of COVID-19 susceptibility/hospitalization/non-hospitalization and long COVID.

Phenome-Wide Analysis of Gene Expression Associations with Candidate Genes

To investigate gene expression associations with acute-phase COVID-19 and long COVID-related

phenotypes, we performed a phenome-wide analysis of gene expression associations (Pheno-TWAS)

analysis targeting adjacent genes located within a 1Mb-window of 62 candidate SNPs previously linked to

COVID-19. Of the 918 tested TWAS genes, 400 genes (43.6%), including 87 associated with *HLA* loci (e.g.,

HLA-DQA2, *HLA-A*, and *HLA-C*; Fig. S17-19), passed a stringent Bonferroni-adjusted significance

threshold ($P < 2.7 \times 10^{-9}$). Genes located near *HLA* loci emerged as top hits, demonstrating significant

associations with immune-related disorders such as asthma, rheumatoid arthritis, psoriasis, coeliac disease,

and systemic lupus erythematosus—conditions that may contribute to acute COVID-19 or long COVID. In

addition to *HLA*-associated loci, other 313 genes across 44 non-*HLA* loci surpassed the genome-wide

significance threshold in TWASs. Key findings include: (1) *IFNAR2*: strongly associated with COVID-19

hospitalization ($P = 2.6 \times 10^{-10}$; Fig. S20); (2) *GSDMB*: linked to asthma ($P = 2.7 \times 10^{-57}$; Fig. S21); (3) *BPTF*:

associated with trunk fat percentage ($P = 1 \times 10^{-18}$; Fig. S22); (4) *CCDC171*: associated with body fat

percentage ($P = 2 \times 10^{-35}$; Fig. S23). Interestingly, *FOXP4* expression, which did not exhibit significant

associations with long COVID phenotypes in prior TWASs, demonstrated a suggestive association with

sleep duration ($P = 1.1 \times 10^{-5}$; Fig. S24). This finding highlights the potential for phenome-wide approaches

to uncover previously uncharacterized associations relevant to acute COVID-19 or long COVID. In total,

Pheno-TWAS identified 45 candidate SNPs associated with genome-wide significant expression-linked

phenotypes. These include three major *HLA* loci (*HLA-DQA2*, *HLA-A*, and *HLA-C*) as well as non-*HLA*

loci such as *IFNAR2*, *BPTF*, *CCDC171*, and *GSDMB*. The implicated phenotypes—ranging from COVID-

19 hospitalization and immune disorders to body composition traits and sleep duration—provide a broad

spectrum of potential biological pathways linking to acute COVID-19 or long COVID pathophysiology.

Full results, including nominally significant associations, are provided in Table S8.

Discussion

Long COVID, characterized by over 200 symptoms spanning multiple organ systems, presents significant

challenges for GWAS due to difficulties in assembling large, representative cohorts. To date, only four genome-wide significant loci—*FOXP4*, *ABO*, *HLA-DQA1*, and *BPTF*—have been identified for long COVID[5,9]. Our integrative analysis identifies 62 candidate loci associated with acute-phase COVID-19 phenotypes, such as COVID-19 susceptibility, hospitalization, and non-hospitalization. These candidate SNPs were obtained by leveraging large-scale COVID-19 GWAS datasets from the HGI. This approach provide potential candidates for validation in future long COVID studies, as currently published long COVID GWASs have the inherent limitations of limited sample sizes and phenotype heterogeneity, and SARS-CoV-2 susceptibility and COVID-19 hospitalization can be used as proxy phenotypes to study long COVID in the future. By categorizing genetic variants into three groups—those associated with hospitalized COVID-19, those linked to both hospitalized and non-hospitalized cases, and those specific to non-hospitalized cases—our findings reveal new insights about potential SNPs that might be associated with long COVID.

There are 42 SNPs prioritized to be associated with either COVID-19 hospitalization or both COVID-19 hospitalization and non-hospitalizaiton, including well-documented variants such as rs12660421 (*FOXP4*) and rs505922 (*ABO*), which have been implicated in severe COVID-19 outcomes and long COVID susceptibility. Notably, additional loci like rs17219281 (*HLA-DQA1*), rs9260038 (*HLA-A*), rs1634761 (*HLA-C*), rs7251000 (*DPP9*), rs9916158 (*GSDMB*), rs12602210 (*BPTF*), rs17078348 (*CCR1*), and rs41264915 (*THBS3*), rs190509934 (*ACE2*) and rs12329760 (*TMPRSS2*) were identified. Furthermore, a unique category comprising 20 SNPs emerged specifically in non-hospitalized COVID-19 cases. These include rs62401842 (*KCTD16*) and rs56143829 (*WASF3*), mapped to genes enriched in brain-related functions, strongly suggesting their potential involvement in long COVID. However, future investigations are warranted for these candidate SNP-gene pairs in long COVID.

While this approach provides critical insights, certain limitations warrant consideration. First, the reliance on proxy phenotypes may obscure SNPs specific to mild COVID-19 cases, given the skewed representation of hospitalized patients in HGI datasets. Indeed, non-hospitalized-specific SNPs did not reach genome-wide significance, likely reflecting this bias. Nevertheless, 20 suggestive SNPs, enriched near genes implicated in neurocognitive and age-related pathways, merit further validation in independent cohorts. Second, the TWAS conducted using S-MetaXcan are constrained by the limited tissue specificity of available GTEx datasets and COVID related GWASs. Despite identifying 7 loci—*HLA-DQA1*, *HLA-A*, *HLA-C*, *DPP9*, *CCR1*, *THBS3*, *GSDMB*—that emerged as promising TWAS hits for long COVID, the potential absence of COVID-19-specific tissues, such as nasopharyngeal or immune-relevant sites, may hinder the detection of tissue-specific effects pertinent to acute-phase COVID-19 and long COVID. Finally, while our approach

offers new insights into long COVID, we acknowledge that proxy-based inference carries inherent
uncertainty. The overlaps observed with long COVID loci are suggestive rather than confirmatory.
Nonetheless, the concordance of TWAS-implicated genes and Pheno-TWAS-trait enrichment supports the
biological plausibility association between acute-phase COVID-19 and long COVID. Future efforts should
validate these findings in larger, dedicated long COVID cohorts with more refined phenotypes. Until then,
our results serve as a resource for prioritizing loci for further investigation in post-acute COVID research.

In conclusion, our findings underscore the utility of integrative approaches to prioritize genetic risk loci for
future investigation of long COVID. The discovery of loci such as *FOXP4*, *ABO*, and *HLA-DQA1*, as well
as *BPTF*, suggests potentially shared biological pathways between acute COVID-19 severity and its chronic
manifestations, such as long COVID. Additionally, the identification of brain-enriched loci in non-
hospitalized cases aligns with emerging evidence linking long COVID to neuroinflammatory and
neurodegenerative processes. Future studies, particularly those incorporating diverse populations and long-
term follow-up data, are essential to refine these associations and unravel the intricate mechanisms
underlying long COVID.

Ethics approval and consent to participate

All data used in this study were freely shared by other researchers. Since no patient-identifiable information
was involved, ethical approval and informed consent were not applicable.

Consent for publication

This study is a secondary analysis of publicly available COVID-19 and long COVID-related GWAS data.
No individual-identifiable information, such as personal identifiers or images, were used; therefore, consent
for publication is not applicable.

Availability of data and material

All data are freely accessible upon request by contacting the corresponding author, Z.C., at
cheng.zhong.shan@gmail.com.

Declaration of interests

The authors declare no competing interests.

Funding

No funding is available for supporting current study.

Authors' contributions

Z.C. conceived the study, analyzed the data, and wrote the manuscript.

Acknowledgements

I am thankful to all researchers who participated and contributed to the HGI and GRASP project, as their

generosities in freely sharing these COVID-19 hospitalization GWASs and other COVID-19/long COVID

related GWASs are essential for the current investigation.

TABLES

Table 1. Candidate SNPs likely associated with either COVID-19 hospitalization or both COVID-19

hospitalization and non-hospitalization

Variant information					HGI-B1			HGI-B2			HGI-C2			HGI-B1-vs-B2	COVID-19
chr	pos	rsid	allele	AF	gene	beta	se	p	beta	se	p	beta	se	p	DiffPval	SNP groups
1	47275770	rs10890422	C	0.402	CYP4B1	-0.05	0.02	3.28E-03	-0.05	0.01	4.43E-08	-0.02	0.00	1.10E-04	6.63E-01	Hosp
1	65412830	rs11208552	T	0.647	JAK1	-0.01	0.02	6.95E-01	-0.05	0.01	2.19E-09	-0.02	0.00	4.21E-04	5.14E-03	Both
1	77949123	rs7515509	A	0.366	AK5	0.08	0.02	5.71E-06	0.06	0.01	2.94E-12	0.02	0.00	2.16E-05	1.82E-01	Hosp
1	155167786	rs41264915	G	0.103	THBS3	-0.10	0.03	3.59E-04	-0.13	0.01	9.33E-23	-0.02	0.01	1.13E-03	2.64E-01	Hosp
2	26833309	rs1275969	T	0.560	CIB4	0.04	0.02	2.37E-02	0.05	0.01	2.03E-08	0.01	0.00	9.18E-03	8.15E-01	Hosp
2	60707588	rs1123573	G	0.367	BCL11A	-0.03	0.02	1.86E-01	-0.07	0.01	1.32E-14	-0.03	0.00	4.62E-09	1.84E-02	Both
2	198245297	rs150345524	A	0.413	SF3B1	0.05	0.02	1.69E-02	0.05	0.01	5.56E-08	0.01	0.00	4.66E-02	9.52E-01	Hosp
3	45847241	rs17078348	G	0.101	SLC6A20	0.29	0.03	1.15E-19	0.34	0.01	2.53E-130	0.08	0.01	2.01E-36	6.34E-02	Hosp
3	101525625	rs2290859	T	0.341	NXPE3	-0.03	0.02	1.55E-01	-0.07	0.01	2.34E-13	-0.05	0.00	4.43E-31	2.02E-02	Both
4	25435159	rs7684660	C	0.829	ANAPC4	-0.06	0.03	1.98E-02	-0.08	0.01	8.71E-12	-0.02	0.00	2.86E-05	4.57E-01	Hosp
5	131776967	rs10066378	C	0.131	SLC22A5	0.06	0.02	1.80E-02	0.07	0.01	1.63E-10	0.02	0.01	1.00E-03	4.94E-01	Hosp
6	29907544	rs9260038	G	0.622	HLA-A	-0.04	0.02	2.72E-02	-0.06	0.01	1.94E-10	-0.01	0.00	1.30E-02	3.40E-01	Hosp
6	31274027	rs1634761	T	0.500	HLA-C	-0.04	0.02	1.81E-02	-0.06	0.01	4.50E-12	-0.02	0.00	9.99E-07	2.95E-01	Hosp
6	32675645	rs17219281	A	0.072	HLA-DQA1	-0.10	0.04	1.01E-02	-0.12	0.02	5.53E-11	-0.03	0.01	1.81E-03	5.30E-01	Hosp
6	41488378	rs12660421	A	0.041	FOXP4	0.26	0.04	2.88E-10	0.24	0.02	2.82E-31	0.08	0.01	7.36E-15	6.55E-01	Hosp
7	99630342	rs2897075	T	0.364	ZKSCAN1	0.01	0.02	7.21E-01	0.05	0.01	8.92E-09	0.02	0.00	6.17E-06	7.17E-03	Both
7	100220850	rs11766643	G	0.204	TFR2	-0.05	0.02	2.45E-02	-0.04	0.01	4.71E-04	-0.03	0.01	7.46E-08	4.92E-01	Hosp
8	61537523	rs1120591	C	0.393	RAB2A	0.02	0.02	2.75E-01	0.05	0.01	8.64E-10	0.02	0.00	2.48E-05	4.32E-02	Both
9	15795833	rs79611697	T	0.068	CCDC171	0.08	0.04	3.75E-02	0.10	0.02	3.57E-08	0.03	0.01	3.26E-03	4.72E-01	Hosp
9	21172825	rs149533170	A	0.009	IFNA21	0.06	0.11	6.03E-01	0.28	0.05	1.38E-08	0.08	0.03	7.64E-04	2.21E-02	Both
9	136149229	rs505922	T	0.348	ABO	0.01	0.02	6.16E-01	0.09	0.01	4.14E-24	0.08	0.00	7.93E-90	2.33E-06	Both
10	81723695	rs61860402	T	0.112	SFTPD	0.08	0.03	2.65E-03	0.08	0.01	1.38E-10	0.03	0.01	2.76E-08	9.61E-01	Hosp
11	1241221	rs35705950	T	0.100	MUC5B	-0.09	0.03	3.84E-03	-0.10	0.01	3.41E-12	-0.02	0.00	3.31E-03	6.00E-01	Hosp
11	34529831	rs2924480	C	0.399	ELF5	-0.03	0.02	1.67E-01	-0.08	0.01	1.63E-16	-0.02	0.00	1.59E-06	1.31E-02	Both
12	113374748	rs10774679	T	0.653	OAS3	0.04	0.02	2.31E-02	0.07	0.01	3.25E-16	0.03	0.00	4.75E-10	7.42E-02	Hosp
12	133141973	rs5023077	C	0.513	FBRSL1	-0.05	0.02	1.03E-02	-0.07	0.01	2.84E-15	-0.02	0.00	3.14E-07	1.79E-01	Hosp
13	113535741	rs12585036	T	0.209	ATP11A	0.07	0.02	4.58E-04	0.10	0.01	3.15E-21	0.02	0.01	2.85E-06	2.22E-01	Hosp
14	29497258	rs150497803	T	0.043	FOXG1	0.00	0.05	9.79E-01	-0.09	0.02	6.68E-05	-0.07	0.01	2.79E-10	3.11E-02	Both
16	89262657	rs117169628	A	0.135	SLC22A31	0.09	0.03	4.68E-04	0.10	0.01	1.37E-14	0.03	0.01	2.78E-05	7.97E-01	Hosp
17	38182229	rs9916158	T	0.365	GSDMA/B	-0.01	0.02	4.85E-01	0.03	0.01	2.05E-04	0.02	0.00	1.11E-08	5.88E-03	Both
17	44057595	rs3785884	A	0.187	MAPT	-0.05	0.02	2.22E-02	-0.09	0.01	3.84E-16	-0.02	0.01	3.51E-04	6.69E-02	Hosp
17	44787312	rs1378358	T	0.167	NSF	-0.04	0.02	9.81E-02	-0.08	0.01	1.18E-13	-0.02	0.01	2.58E-03	2.75E-02	Both
17	47950329	rs75432325	C	0.042	TAC4	0.08	0.04	5.82E-02	0.18	0.02	2.24E-19	0.05	0.01	7.00E-07	2.04E-02	Both
19	4714468	rs7251000	T	0.432	DPP9	-0.07	0.02	3.98E-04	-0.08	0.01	1.17E-19	-0.03	0.00	1.18E-11	4.61E-01	Hosp
19	9009161	rs12976386	T	0.552	MUC16	0.04	0.03	1.14E-01	-0.03	0.01	9.37E-03	-0.03	0.01	3.75E-08	2.43E-03	Both
19	10463118	rs34536443	C	0.043	TYK2	0.05	0.06	3.58E-01	0.23	0.02	1.74E-21	0.05	0.01	1.29E-05	4.66E-04	Both
19	49206417	rs492602	G	0.460	FUT2	-0.02	0.02	1.69E-01	-0.06	0.01	1.71E-11	-0.04	0.00	3.44E-18	4.00E-02	Both
19	50882619	rs1405655	C	0.332	NR1H2	0.07	0.02	6.03E-05	0.08	0.01	5.92E-19	0.03	0.00	1.20E-09	7.95E-01	Hosp
21	34621948	rs2834164	C	0.480	IFNAR2	-0.10	0.02	1.51E-08	-0.11	0.01	4.14E-41	-0.03	0.00	6.54E-14	4.83E-01	Hosp
21	35353264	rs76608815	T	0.090	SLC5A3	0.11	0.03	9.64E-05	0.13	0.01	6.60E-21	0.04	0.01	1.49E-07	4.83E-01	Hosp
21	42852497	rs12329760	T	0.258	TMPRSS2	-0.07	0.02	8.60E-04	-0.06	0.01	2.16E-08	-0.01	0.00	5.32E-03	4.55E-01	Hosp
23	15620340	rs190509934	C	0.003	ACE2	-0.46	0.20	2.12E-02	-0.44	0.10	1.08E-05	-0.36	0.04	1.70E-18	9.38E-01	Hosp

Note: HGI: the COVID-19 host genetics initiative; chr: chromosome; pos: hg38 genomic position; allele:

alternative allele; AF: allele frequency of alternative allele; diffPval: statistical significance P for

differential effect size of each common SNP by comparing the two HGI GWASs, including HGI-B1 and

HGI-B2; Hosp: SNPs tend to be more specifically emerged in hospitalized COVID-19 cases; Both: SNPs

tend to be emerged in both hospitalized and non-hospitalized COVID-19 cases. Association Ps passed the

suggestive genome-wide association significance threshold of $P < 1\times10^{-7}$ are highlighted in light red color,

and differential effect size significance (DiffPval) $P < 0.05$ is colored with light green. Note: HGI-C2

(SASR-CoV2 susceptibility vs. general population), HGI-B1 (hospitalized vs. non-hospitalized COVID-

19), and HGI-B2 (hospitalized vs. general population).

Table 2. Candidate SNPs specifically associated with non-hospitalized COVID-19 cases

chr	pos	rsid	allele	AF	gene	beta	se	p	beta	se	p	beta	se	p	DiffPval
	Variant information					HGI-B1			HGI-B2			HGI-C2			HGI-B1-vs-B2
3	174147743	rs9799354	C	0.556	NLGN1	0.08	0.02	5.38E-06	0.01	0.01	2.71E-01	-0.01	0.00	1.79E-02	6.21E-06
5	128241667	rs201484359	G	0.304	SLC27A6	0.13	0.03	8.55E-06	0.02	0.01	1.25E-01	-0.01	0.01	8.91E-02	2.58E-05
5	143904835	rs62401842	A	0.042	KCTD16	0.27	0.06	8.53E-07	0.02	0.03	3.82E-01	0.00	0.01	8.72E-01	3.18E-07
5	175248251	rs112842080	T	0.021	CPLX2	-0.36	0.07	1.58E-06	-0.04	0.03	2.53E-01	0.03	0.02	6.69E-02	1.25E-06
6	37086436	rs147171940	A	0.038	PIM1	-0.19	0.04	5.96E-06	-0.04	0.02	1.33E-01	0.01	0.01	5.74E-01	5.92E-05
6	151444801	rs76392050	T	0.010	MTHFD1L	0.70	0.16	6.10E-06	0.10	0.06	6.16E-02	0.03	0.03	3.84E-01	5.88E-06
8	57438048	rs4737438	A	0.378	PENK	0.08	0.02	2.97E-06	0.01	0.01	2.79E-01	0.00	0.00	5.30E-01	2.98E-06
8	68035003	rs148340257	T	0.065	CSPP1	-0.22	0.05	8.05E-06	-0.03	0.02	1.77E-01	0.00	0.01	8.82E-01	7.21E-06
9	123344199	rs10760104	T	0.819	CDK5RAP2	-0.13	0.03	2.37E-06	-0.01	0.01	4.57E-01	0.00	0.01	8.77E-01	5.36E-07
10	54976003	rs55654117	C	0.272	MBL2	0.10	0.02	1.85E-06	0.01	0.01	2.61E-01	0.00	0.00	4.50E-01	1.13E-06
10	84981211	rs61858037	T	0.091	NRG3	0.15	0.03	9.21E-06	0.02	0.02	1.62E-01	0.00	0.01	9.58E-01	2.31E-05
12	39502966	rs61939166	G	0.011	KIF21A	-0.40	0.09	3.60E-06	-0.03	0.04	5.36E-01	-0.02	0.02	3.63E-01	1.10E-06
12	78552292	rs367777	T	0.358	NAV3	-0.10	0.02	3.13E-06	-0.01	0.01	2.77E-01	0.01	0.00	2.39E-01	1.89E-06
13	27062460	rs56143829	T	0.025	WASF3	0.24	0.05	1.26E-06	0.01	0.03	6.03E-01	0.00	0.01	7.56E-01	3.23E-07
13	63988259	rs9570861	A	0.552	PCDH20	0.08	0.02	5.51E-06	0.02	0.01	1.07E-01	-0.01	0.00	4.06E-02	4.83E-05
14	32937383	rs11454577	G	0.589	AKAP6	-0.09	0.02	5.54E-06	-0.01	0.01	3.22E-01	0.00	0.01	6.24E-01	7.71E-06
16	84887921	rs113067468	G	0.030	CRISPLD2	-0.30	0.07	4.48E-06	-0.05	0.03	1.20E-01	0.00	0.02	8.21E-01	2.18E-05
17	3454928	rs115744301	G	0.035	TRPV3	0.66	0.15	5.21E-06	0.02	0.05	6.89E-01	-0.03	0.03	2.52E-01	2.53E-07
17	13775336	rs11869231	T	0.310	COX10	-0.11	0.02	2.38E-06	0.00	0.01	6.52E-01	0.00	0.00	9.85E-01	2.26E-07
20	24627964	rs6049828	C	0.567	SYNDIG1	0.09	0.02	7.13E-06	0.01	0.01	2.65E-01	0.00	0.00	3.51E-01	5.43E-06

586 Note: abbreviations in the table headers are similar to that of Table 1.

SUPPLEMENTARY TABLES

Table S1. COVID-19 GWASs and long COVID GWASs included in current study for prioritizing candidate SNPs

Table S2. Transcriptome-wide association studies (TWAS) curated and used in current study

Table S3. Association signals for these 62 prioritized candidate SNPs in Long COVID GWASs from HGI

Table S4. Association signals for adjacent SNPs of these 62 prioritized candidate SNPs in Long COVID GWASs from HGI

Table S5. Association signals for published long COVID SNPs across 4 HGI COVID-19 GWASs

Table S6 Top genes associated with acute-phase COVID-19 susceptibility and hospitalization across 48 GTEx tissues in transcriptome-wide association studies (TWAS)

599 **Table S7. Long COVID association signals for the adjacent genes of these 62 candidate SNPs that**
600 **pass the nominal significance in the transcriptome-wide association studies (TWAS) of COVID-19**
601 **hospitalization and susceptibility**

602 **Table S8. Adjacent genes of these 62 candidate SNPs that pass the nominal significance threshold in**
603 **the phenome-wide transcriptome association studies (Pheno-TWASs)**

 FIGURES

Figure 1. Workflow for prioritizing genetic single nucleotide polymorphisms (SNPs) associated with

either COVID-19 hospitalization or non-hospitalization or both as well as its association with sex-

stratified COVID-19 hospitalization and long COVID

An integrative analysis workflow is developed to analyze acute-phase COVID-19 GWAS, including HGI-

C2 (SARS-CoV2 infected cases vs. general population), HGI-B1 (hospitalized COVID-19 vs. non-

hospitalized COVID-19), and HGI-B2 (hospitalized COVID-19 vs. general population), as well as the

differential GWAS (HGI-B1-vs-B2) generated in current study by comparing effect sizes of each SNPs

between HGI-B1 and HGI-B2. Three groups of top candidate SNPs, comprising "Severe COVID-19-

Specific SNPs," "SNPs Associated with Both Severe and Mild COVID-19," and "Mild COVID-19-Specific

SNPs," are obtained by applying different filters of association p-values as demonstrated in the right part

of the figure. These filters result in 62 candidate SNPs that are subsequently subjected to the determination

of their associations with long COVID or sex-biased association with COVID-19 hospitalization. Further

transcriptome-wide association studies and phenotype-wide transcriptome-wide association studies are

conducted to investigate genes adjacent to these candidate SNPs and their association with acute-phase

COVID-19 and long COVID.

Figure 2. Candidate SNPs associated with COVID-19 hospitalization or both hospitalization and non-

hospitalization

(A) 42 top prioritized candidate SNPs, with 27 SNPs specifically associated with hospitalization risk and

15 showing common risk patterns across both hospitalized and non-hospitalized cases. These SNPs were

selected based on the analysis workflow illustrated in Fig. 1, and each SNP is centered within a 1Mb

window in a local Manhattan plot to highlight the genomic context for its association with acute-phase

COVID-19. Key genes near these SNPs, including *FOXP4*—a locus previously implicated as a risk locus

for both acute-phase COVID-19 and long COVID—and other notable COVID-19-associated genes (*ACE2*,

OAS3, *JAK1*, *IFNA2*, *DDP9*, and *ABO*), are annotated to emphasize their potential relevance to SARS-

CoV-2 pathology. (B) Forest plot of 42 SNPs identified from COVID-19 GWAS on susceptibility (HGI-

C2) and hospitalization (HGI-B1 and HGI-B2), showing suggestive ($P<1\text{x}10^{-7}$ or genome-wide significant

associations ($P<5\text{x}10^{-8}$). Allele distributions are compared between hospitalized and non-hospitalized cases

(HGI-B1). SNPs are grouped as follows: (1) hospitalization-specific, genome-wide significant (Hosp-

specific, $P<5\text{x}10^{-8}$); (2) common across cases, genome-wide significant (Common, $P<5\text{x}10^{-8}$); (3)

hospitalization-specific, suggestive or non-significant (hosp-specific, $P = (5\text{x}10^{-8}, 1]$); (4) common across

cases, suggestive or non-significant (Common, $P = (5\text{x}10^{-8}, 1]$). Colored dots represent odds ratios (ORs)

with 95% confidence intervals (CIs) as error bars. ORs with CIs overlapping the vertical line (OR = 1)

indicate no significance.

Figure 3. Evaluation of top genes adjacent to prioritized candidate SNPs (n=62) in transcriptome-

wide association studies (TWAS) of COVID-19 susceptibility, hospitalization, and long COVID

(A) Bar plot showing the top genes adjacent to prioritized candidate SNPs based on transcriptome-wide

association studies (TWAS) for COVID-19 susceptibility and hospitalization, as well as long COVID.

Genes are categorized by the GTEx tissue in which they display the most significant association. Besides

rs17078348, other two SNPs have multiple genes with the smallest TWAS P are highlighted. (B) Heatmap

depicting the significance of gene-tissue associations for prioritized SNP-adjacent genes across 48 GTEx

tissues. Each cell represents the P for a specific gene in a given tissue, with a color gradient indicating

statistical significance: gray ($P>0.05$), yellow ($P<0.05$), and red ($P<1\times10^{-6}$). Genes are sorted by TWAS

names, and GTEx tissues are clustered to highlight patterns of tissue specificity.

Figure 4. Top genes adjacent to prioritized candidate SNPs (n=23) in long COVID related
transcriptome-wide association studies (TWASs)

Bar plots illustrating the best P across 48 GTEx tissues for genes adjacent to prioritized candidate SNPs

(n=23) in 4 long COVID TWASs.

SUPPLEMENTARY FIGURES

Figure S1. QQ plots for four COVID-19 GWASs from HGI

Figure S2. Local Manhattan plots for candidate SNPs more likely associated with hospitalized than non-hospitalized COVID-19

Figure S3. Local Manhattan plots for candidate SNPs likely associated with both hospitalized and non-hospitalized COVID-19

Figure S4. Evaluation of prioritized candidate SNPs that tend to be either more likely associated with COVID-19 hospitalization or commonly associated with both hospitalization and non-hospitalization of COVID-19 in sex-biased COVID-19 hospitalization GWAS from UK Biobank

(A-B) Manhattan plots and QQ plots for sex-stratified COVID-19 hospitalization GWASs, as well as the differential effect size GWAS between females and males. (C) Local Manhattan plot for these 42 SNPs separated into two groups, including candidate SNPs that tend to be specific in hospitalized cases and that are more frequent in both hospitalized and non-hospitalized cases. All association signals shown in the figure are within a 100Mb genomic window for each candidate SNP residing in the middle. Genes close to these 42 SNPs are added into the upper track. (C) Forest plots for these 42 candidate SNPs in sex-stratified COVID-19 hospitalization GWASs, as well as the differential effect size GWAS between females and males. Odd Ratios (ORs) and the corresponding 95% confidence intervals (CI) of these SNPs are illustrated, with SNPs showing nominal significant associations among female or male COVID-19 patients are colored in dark red and indicated by '*'. Note that there are 8 and 6 SNPs showing sex-biased associations with females and males, respectively, meanwhile, only one SNP rs17078348 mapped to *SLC6A20* displaying nominally significant association signals in both sexes. The genomic position of rs190509934 is used to collect all other SNPs around it, as it is not included in the two UKB sex-stratified COVID-19 hospitalization GWASs.

Figure S5. Local Manhattan plots for candidate SNPs either more likely associated with COVID-19 hospitalization or commonly associated with both hospitalization and non-hospitalization of COVID-19 in sex-biased COVID-19 hospitalization GWAS from UK Biobank

Figure S6. Local Manhattan plots for candidate SNPs specifically associated with non-hospitalized COVID-19

Figure S7. Evaluation of candidate SNPs associated with non-hospitalized COVID-19 in sex-biased COVID-19 hospitalization GWAS from UK Biobank

(A) Local Manhattan plots for candidate SNPs identified exclusively in the non-hospitalized COVID-19

group in sex-stratified COVID-19 hospitalization GWAS (the differential effect size GWAS between

females and males put on the top, female GWAS added in the middle, and male GWAS shown at the

bottom). (B) Forest plots displaying the odds ratios (ORs) and its corresponding 95% confidence intervals

(CIs) of these SNPs in non-hospitalized COVID-19 patients from the sex-stratified GWAS (male results on

the top and female results at the bottom). SNPs with nominally significant associations in either female or

male groups are highlighted in dark red and marked with an asterisk (*). Notably, three SNPs exhibit male-

biased associations with COVID-19 hospitalization. (C-H) Detailed local Manhattan plots for six prioritized

SNPs specifically identified in the non-hospitalized COVID-19 group within the sex-stratified GWAS.

Figure S8. Local Manhattan plots for SNPs in the SNP category "Severe COVID-19-Specific SNPs"

across 4 long COVID GWASs

Each target SNP is located at the center of each local Manhattan plot, and its linked gene is put along SNP

rsid at the bottom of the figure.

Figure S9. Local Manhattan plots for SNPs in the two SNP categories, including "Mild COVID-19-

Specific SNPs" and "SNPs Associated with Both Severe and Mild COVID-19" across 4 long COVID

GWASs

Figure annotation is similar to that of Figure S8.

Figure S10. Forest plots for 62 candidate SNPs and its adjacent SNPs passed the association threshold

of *P*<0.001 in at least one of four long COVID GWASs

SNPs adjacent to candidate SNPs that are prioritized from 4 HGI COVID-19 GWASs (colored according

to its membership to 3 SNP categories in Figure 1) are indicated by adding "+" after the corresponding

gene. "*" represents the SNP's association with long COVID is nominally significant. To the sake of clarity,

the OR is restricted to be less than 2. SNPs that are not include in specific long COVID GWASs show no

OR and 95% CI in the forest plots.

Figure S11. Evaluation of other published long COVID SNPs in the current HGI COVID-19 GWASs

(A) Forest plots for 15 published long COVID SNPs in currently acute-phase COVID-19 GWASs (from

left to right: HGI-B1, HGI-B2, and HGI-C2), with genes closed to each of them listed on the right-y-axis.

Note: beside 3 long COVID risk SNPs reported by Chaudhary et al., other 12 long COVID SNPs were

obtained by screening 83 previously reported long COVID SNPs by Taylor et al. (see Table S5) that show

nominally significant association in at least one of the 3 acute-phase COVID-19 GWASs. (B-G) Local

Manhattan plots illustrate published long COVID SNPs approximate to these top candidate SNPs identified

in current study with each candidate SNP is located in the center of each genomic window; GWAS labels

from bottom to top in each panel are HGI-B1, HGI-B2, HGI-B1-vs-B2, and HGI-C2, respectively.

Figure S12. Total number of genes adjacent to prioritized candidate SNPs (n=62) as well as total

number of genes that were tested and passed different association thresholds in COVID-19

transcriptome-wide association studies (TWASs)

Bar plots illustrating the number of genes adjacent to prioritized candidate SNPs (n=62) as well as number

of adjacent genes tested and passed different association P thresholds in TWASs. Note that the 62 SNPs

are colored according to its corresponding SNP category as depicted in Figure 1. There are 4 acute-phase

COVID-19 related TWASs and 4 long COVID TWASs performed across 48 GTEx tissues.

Figure S13. Transcriptome-wide association studies (TWAS) for COVID-19 susceptibility,
hospitalization, and long COVID

(A) Top genome-wide significant TWAS-identified genes associated with COVID-19 susceptibility and

hospitalization, annotated by their best significant tissue expression association (based on 48 GTEx tissues).

No genes reached genome-wide significance in TWAS analyses of long COVID-related GWASs. (B)

Manhattan plots depicting TWAS results for COVID-19 susceptibility, and hospitalization (HGI datasets),

as well as long COVID GWASs (LongCOVID-N1, LongCOVID-N2, LongCOVID-W1, and LongCOVID-

W2) derived from four distinct case-control designs (see Table S1). Each dot represents a gene, with its

genomic position along the x-axis and -log10(P) on the y-axis.

Figure S14. Evaluation of top genes emerged from transcriptome-wide association studies (TWAS)
of COVID-19 susceptibility and hospitalization in the corresponding long COVID-related TWASs

Heatmap displaying the significance (P) of top genes identified in TWAS analyses of COVID-19

susceptibility and hospitalization across multiple tissues in long COVID-related TWASs. Each cell

represents the P for the association of a gene with long COVID in a specific tissue from GTEx database.

The color gradient denotes statistical significance: blue ($P>0.05$), yellow ($P<0.05$), and red ($P<1\times10^{-6}$).

Rows are sorted by genes, and columns represent tissues, allowing visualization of tissue-specific patterns

of gene expression relevance.

Figure S15. Other top genes adjacent to prioritized candidate SNPs (n=29) in long COVID-19
transcriptome-wide association studies (TWASs)

Bar plots illustrating the best *P* for genes adjacent to prioritized candidate SNPs (n=29) in 4 long COVID
TWASs across 48 GTEx tissues, which is a supplement to Figure 4.

Figure S16. Evaluation of top genes adjacent to prioritized candidate SNPs (n=62) in transcriptome-
wide association studies (TWASs) of long COVID across 48 GTEx tissues

(A) Bar plot showing the number of SNP-gene pairs passed the nominal TWAS association threshold in
GTEx tissues. Note that SNP-gene pairs are defined by combining prioritized candidate SNPs with its
adjacent genes. (B) Heatmap depicting the significance (*P*) of SNP-gene pairs across 48 GTEx tissues in
long COVID TWASs. Each cell represents the *P* for a specific gene in a given tissue, with a color gradient
indicating statistical significance: white (*P*>0.05), yellow (*P*<0.05), and red (*P*<1E-6). Genes are sorted by
SNP-gene pairs and TWAS names.

Figure S17. Evaluation of genes adjacent to prioritized candidate SNP rs17219281 (*HLA-DQA1*) in
phenome-transcriptome-wide association studies (Pheno-TWAS) across 48 GTEx tissues

To the sake of clarity, heatmap only depicting the significance of SNP-gene pairs with $P<1\times10^{-60}$ across 48
GTEx tissues in TWASs. Each cell represents the *P* for a specific gene in a given tissue, with blank cell
indicating the *P* not passed the threshold of $P<1\times10^{-60}$.

Figure S18. Evaluation of genes adjacent to prioritized candidate SNP rs9260038 (*HLA-A*) in
phenome-transcriptome-wide association studies (Pheno-TWAS) across 48 GTEx tissues

Annotation is similar to heatmap as that in Figure S17.

Figure S19. Evaluation of genes adjacent to prioritized candidate SNP rs1634761 (*HLA-C*) in
phenome-transcriptome-wide association studies (Pheno-TWAS) across 48 GTEx tissues

Annotation is similar to heatmap as that in Figure S17.

Figure S20. Evaluation of genes adjacent to prioritized candidate SNP rs2834164 (*IFNAR2*) in
phenome-transcriptome-wide association studies (Pheno-TWAS) across 48 GTEx tissues

To the sake of clarity, the color gradient of heatmap denotes statistical significance: blue ($P>0.05$), yellow

($P<0.05$), and red ($P<11 \times 10^{-6}$). Rows are sorted by genes, and columns represent TWAS names, allowing

visualization of tissue-specific patterns of gene expression relevance across 48 GTEx tissues in TWASs.

Figure S21. Evaluation of genes adjacent to prioritized candidate SNP rs9916158 (*GSDMA/B*) in

phenome-transcriptome-wide association studies (Pheno-TWAS) across 48 GTEx tissues

Heatmap legend as that in Figure S20

Figure S22. Evaluation of genes adjacent to prioritized candidate SNP rs12602210 (*BPTF*) in

phenome-transcriptome-wide association studies (Pheno-TWAS) across 48 GTEx tissues

Heatmap legend as that in Figure S20

Figure S23. Evaluation of genes adjacent to prioritized candidate SNP rs79611697 (*CCDC171*) in

phenome-transcriptome-wide association studies (Pheno-TWAS) across 48 GTEx tissues

Heatmap legend as that in Figure S20

Figure S24. Evaluation of genes adjacent to prioritized candidate SNP rs12660421 (*FOXP4*) in

phenome-transcriptome-wide association studies (Pheno-TWAS) across 48 GTEx tissues

Heatmap legend as that in Figure S20

References

788
1.   Ely, E.W., Brown, L.M., Fineberg, H.V., National Academies of Sciences, E., and Medicine Committee on
Examining the Working Definition for Long, C. (2024). Long Covid Defined. N Engl J Med *391*, 1746-1753.
10.1056/NEJMsb2408466.
2.   Lammi, V., Nakanishi, T., Jones, S.E., Andrews, S.J., Karjalainen, J., Cortes, B., O'Brien, H.E., Ochoa-
Guzman, A., Fulton-Howard, B.E., Broberg, M., et al. (2025). Genome-wide association study of long
COVID. Nat Genet. 10.1038/s41588-025-02100-w.
3.   Luo, Y.-S., Zhang, K., and Cheng, Z.-S. (2023). Absence of Association between a Long COVID and Severe
COVID-19 Risk Variant of FOXP4 and Lung Cancer. Frontiers in genetics *14*. 10.3389/fgene.2023.1258829.
4.   Taylor, K., Pearson, M., Das, S., Sardell, J., Chocian, K., and Gardner, S. (2023). Genetic risk factors for
severe and fatigue dominant long COVID and commonalities with ME/CFS identified by combinatorial
analysis. Journal of translational medicine *21*, 775. 10.1186/s12967-023-04588-4.
5.   Chaudhary, N.S., Weldon, C.H., Nandakumar, P., Team, a.R., Holmes, M.V., and Aslibekyan, S. (2024).
Multi-ancestry GWAS of Long COVID identifies immune-related loci and etiological links to chronic fatigue

802   syndrome, fibromyalgia and depression. medRxiv, 2024.2010.2007.24315052.
803   10.1101/2024.10.07.24315052.
804 6. Covid-Host-Genetics-Initiative (2023). A second update on mapping the human genetic architecture of
805   COVID-19. Nature *621*, E7-E26. 10.1038/s41586-023-06355-3.
806 7. Davis, H.E., McCorkell, L., Vogel, J.M., and Topol, E.J. (2023). Long COVID: major findings, mechanisms and
807   recommendations. Nature reviews. Microbiology *21*, 133-146. 10.1038/s41579-022-00846-2.
808 8. Cai, M., Xie, Y., Topol, E.J., and Al-Aly, Z. (2024). Three-year outcomes of post-acute sequelae of COVID-19.
809   Nat Med *30*, 1564-1573. 10.1038/s41591-024-02987-8.
810 9. Lammi, V., Nakanishi, T., Jones, S.E., Andrews, S.J., Karjalainen, J., Cortés, B., O'Brien, H.E., Fulton-Howard,
811   B.E., Haapaniemi, H.H., Schmidt, A., et al. (2023). Genome-wide Association Study of Long COVID.
812   medRxiv, 2023.2006.2029.23292056. 10.1101/2023.06.29.23292056.
813 10. Cheng, Z., Cai, Y., Zhang, K., Zhang, J., Gui, H., Luo, Y.S., Zhou, J., and DeVeale, B. (2023). MAP3K19
814   regulatory variation in populations with African ancestry may increase COVID-19 severity. iScience *26*,
815   107555. 10.1016/j.isci.2023.107555.
816 11. Bai, F., Tomasoni, D., Falcinella, C., Barbanotti, D., Castoldi, R., Mulè, G., Augello, M., Mondatore, D.,
817   Allegrini, M., Cona, A., et al. (2022). Female gender is associated with long COVID syndrome: a prospective
818   cohort study. Clinical microbiology and infection : the official publication of the European Society of
819   Clinical Microbiology and Infectious Diseases *28*, 611.e619-611.e616. 10.1016/j.cmi.2021.11.002.
820 12. Neuhouser, M.L., Butt, H.I., Hu, C., Shadyab, A.H., Garcia, L., Follis, S., Mouton, C., Harris, H.R., Wactawski-
821   Wende, J., Gower, E.W., et al. (2024). Risk factors for long COVID syndrome in postmenopausal women
822   with previously reported diagnosis of COVID-19. Annals of epidemiology *98*, 36-43.
823   10.1016/j.annepidem.2024.08.003.
824 13. Thibord, F., Chan, M.V., Chen, M.H., and Johnson, A.D. (2022). A year of Covid-19 GWAS results from the
825   GRASP portal reveals potential genetic risk factors. HGG Adv, 100095. 10.1016/j.xhgg.2022.100095.
826 14. Barbeira, A.N., Dickinson, S.P., Bonazzola, R., Zheng, J., Wheeler, H.E., Torres, J.M., Torstenson, E.S., Shah,
827   K.P., Garcia, T., Edwards, T.L., et al. (2018). Exploring the phenotypic consequences of tissue specific gene
828   expression variation inferred from GWAS summary statistics. Nat Commun *9*, 1825. 10.1038/s41467-018-
829   03621-1.
830 15. GTEx-Consortium (2020). The GTEx Consortium atlas of genetic regulatory effects across human tissues.
831   Science *369*, 1318-1330. 10.1126/science.aaz1776.
832 16. Severe-COVID-GWAS-Group, Ellinghaus, D., Degenhardt, F., Bujanda, L., Buti, M., Albillos, A., Invernizzi, P.,
833   Fernandez, J., Prati, D., Baselli, G., et al. (2020). Genomewide Association Study of Severe Covid-19 with
834   Respiratory Failure. N Engl J Med *383*, 1522-1534. 10.1056/NEJMoa2020283.
835 17. Galbraith, M.D., Kinning, K.T., Sullivan, K.D., Araya, P., Smith, K.P., Granrath, R.E., Shaw, J.R., Baxter, R.,
836   Jordan, K.R., Russell, S., et al. (2022). Specialized interferon action in COVID-19. Proc Natl Acad Sci U S A
837   *119*. 10.1073/pnas.2116730119.
838 18. Zabihi Rizi, F., Ghorbani, A., Zahtab, P., Darbaghshahi, N.N., Ataee, N., Pourhamzeh, P., Hamzei, B.,
839   Dolatabadi, N.F., Zamani, A., and Hooshmand, M. (2023). TYK2 single-nucleotide variants associated with
840   the severity of COVID-19 disease. Archives of virology *168*, 119. 10.1007/s00705-023-05729-2.
841 19. Bittner, Z.A., Schrader, M., George, S.E., and Amann, R. (2022). Pyroptosis and Its Role in SARS-CoV-2
842   Infection. Cells *11*. 10.3390/cells11101717.
843 20. Choudhri, Y., Maslove, D.M., and Rauh, M.J. (2023). COVID-19 and the Genetics of Inflammation. Critical
844   care medicine *51*, 817-825. 10.1097/CCM.0000000000005843.
845 21. Pietzner, M., Chua, R.L., Wheeler, E., Jechow, K., Willett, J.D.S., Radbruch, H., Trump, S., Heidecker, B.,
846   Zeberg, H., Heppner, F.L., et al. (2022). ELF5 is a potential respiratory epithelial cell-specific risk gene for
847   severe COVID-19. Nature Communications *13*, 4484. 10.1038/s41467-022-31999-6.
848 22. Hammersen, J., Birndt, S., Dohner, K., Reuken, P., Stallmach, A., Sauerbrey, P., La Rosee, F., Pfirrmann, M.,
849   Fabisch, C., Weiss, M., et al. (2023). The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered
850   hyperinflammation: the RuxCoFlam trial. Leukemia *37*, 1879-1886. 10.1038/s41375-023-01979-w.
851 23. Galeev, A., Suwandi, A., Cepic, A., Basu, M., Baines, J.F., and Grassl, G.A. (2021). The role of the blood
852   group-related glycosyltransferases FUT2 and B4GALNT2 in susceptibility to infectious disease.
853   International journal of medical microbiology : IJMM *311*, 151487. 10.1016/j.ijmm.2021.151487.

24. Rao, S., Baranova, A., Cao, H., Chen, J., Zhang, X., and Zhang, F. (2021). Genetic mechanisms of COVID-19
and its association with smoking and alcohol consumption. Briefings in bioinformatics *22*.
10.1093/bib/bbab284.
25. Matveeva, N., Kiselev, I., Baulina, N., Semina, E., Kakotkin, V., Agapov, M., Kulakova, O., and Favorova, O.
(2023). Shared genetic architecture of COVID-19 and Alzheimer's disease. Frontiers in aging neuroscience
15, 1287322. 10.3389/fnagi.2023.1287322.
26. Simon-Sanchez, J., Schulte, C., Bras, J.M., Sharma, M., Gibbs, J.R., Berg, D., Paisan-Ruiz, C., Lichtner, P.,
Scholz, S.W., Hernandez, D.G., et al. (2009). Genome-wide association study reveals genetic risk
underlying Parkinson's disease. Nat Genet *41*, 1308-1312. 10.1038/ng.487.
27. Lottini, G., Baggiani, M., Chesi, G., D'Orsi, B., Quaranta, P., Lai, M., Pancrazi, L., Onorati, M., Pistello, M.,
Freer, G., and Costa, M. (2022). Zika virus induces FOXG1 nuclear displacement and downregulation in
human neural progenitors. Stem cell reports *17*, 1683-1698. 10.1016/j.stemcr.2022.05.008.
28. Kovanda, A., Lukezic, T., Maver, A., Vokac Krizaj, H., Cizek Sajko, M., Selb, J., Rijavec, M., Bidovec-Stojkovic,
U., Biteznik, B., Rituper, B., et al. (2024). Genomic Landscape of Susceptibility to Severe COVID-19 in the
Slovenian Population. Int J Mol Sci *25*. 10.3390/ijms25147674.
29. Kasela, S., Daniloski, Z., Bollepalli, S., Jordan, T.X., tenOever, B.R., Sanjana, N.E., and Lappalainen, T.
(2021). Integrative approach identifies SLC6A20 and CXCR6 as putative causal genes for the COVID-19
GWAS signal in the 3p21.31 locus. Genome biology *22*, 242. 10.1186/s13059-021-02454-4.
30. Zuo, H., Glaaser, I., Zhao, Y., Kurinov, I., Mosyak, L., Wang, H., Liu, J., Park, J., Frangaj, A., Sturchler, E., et
al. (2019). Structural basis for auxiliary subunit KCTD16 regulation of the GABA(B) receptor. Proc Natl Acad
Sci U S A *116*, 8370-8379. 10.1073/pnas.1903024116.
31. Zhou, S., and Zhang, J. (2021). An epigenome-wide DNA methylation study of patients with COVID-19. *85*,
221-234. 10.1111/ahg.12440.
32. Song, E., Bartley, C.M., Chow, R.D., Ngo, T.T., Jiang, R., Zamecnik, C.R., Dandekar, R., Loudermilk, R.P., Dai,
Y., Liu, F., et al. (2021). Divergent and self-reactive immune responses in the CNS of COVID-19 patients
with neurological symptoms. Cell Reports Medicine *2*, 100288.
https://doi.org/10.1016/j.xcrm.2021.100288.
33. Bartley, C.M., Johns, C., Ngo, T.T., Dandekar, R., Loudermilk, R.L., Alvarenga, B.D., Hawes, I.A., Zamecnik,
C.R., Zorn, K.C., Alexander, J.R., et al. (2021). Anti–SARS-CoV-2 and Autoantibody Profiles in the
Cerebrospinal Fluid of 3 Teenaged Patients With COVID-19 and Subacute Neuropsychiatric Symptoms.
JAMA Neurology *78*, 1503-1509. 10.1001/jamaneurol.2021.3821.
34. Yang, X., Zhu, J., Wang, Q., Tang, B., Shen, Y., Wang, B., Ji, L., Liu, H., and Wuchty, S. (2024). Comparative
analysis of dynamic transcriptomes reveals specific COVID-19 features and pathogenesis of
immunocompromised populations. *9*, e0138523. 10.1128/msystems.01385-23.
35. Wang, P.Y., Ma, J., Kim, Y.C., Son, A.Y., Syed, A.M., Liu, C., Mori, M.P., Huffstutler, R.D., Stolinski, J.L.,
Talagala, S.L., et al. (2023). WASF3 disrupts mitochondrial respiration and may mediate exercise
intolerance in myalgic encephalomyelitis/chronic fatigue syndrome. Proc Natl Acad Sci U S A *120*,
e2302738120. 10.1073/pnas.2302738120.
36. Guruparan, D., and Kumar, S. (2024). Long COVID: G Protein-Coupled Receptors (GPCRs) Associated Genes
and Pathways as a Promising Therapeutic Potential Through Computational Analysis. Preprints. Preprints.
37. Deuis, J.R., Klasfauseweh, T., Walker, L., and Vetter, I. (2024). The 'dispanins' and
related proteins in physiology and neurological disease. Trends in Neurosciences *47*, 622-634.
10.1016/j.tins.2024.06.004.
38. Chester, M.A., and Olsson, M.L. (2001). The ABO blood group gene: a locus of considerable genetic
diversity. Transfusion medicine reviews *15*, 177-200. 10.1053/tmrv.2001.24591.
899

Figure 1

SARS-CoV2 infected vs. general population
(HGI-C2: 159,840 vs. 2,782,977)

P ≤ 0.05

Differential GWAS (HGI-B1 vs. HGI-B2)

P > 0.05   *P* ≤ 0.05   *P* ≤ 0.05

Hospitalized COVID-19 vs. general population
(HGI-B2: 44,986 vs. 2,356,386)

P ≤ 0.05   *P* > 0.05   *P* ≤ 0.05

Hospitalized vs. non-hospitalized COVID-19
(HGI-B1: 16,512 vs. 71,321)

P ≤ 0.05   *P* ≤ 0.05   *P* > 0.05

Independent SNPs with any $P <= 1 \times 10^{-7}$ with same effect size directions among HGI-C2 and HGI-B2

Independent SNPs (MAF>0.01) with any $P <= 1 \times 10^{-5}$ and no other adjacent genome-wide significant SNPs in either HGI-B2 or HGI-C2

Independent SNPs with any $P <= 1 \times 10^{-7}$ with consistent effect size directions between HGI-C2 and HGI-B2

Prioritize each top hit among 4 HGI-GWASs by manually evaluating local Manhattan plots

Category 1: Severe COVID-19-Specific SNPs (n=27)

Category 3: Mild COVID-19-Specific SNPs (n=20)

Category 2: SNPs Associated with Both Severe and Mild COVID-19 (n=15)

Determine association signals for these 62 candidate SNPs in sex-stratified COVID-19 GWASs and long COVID GWASs

Check genes close to these candidate SNPs in transcriptome-wide association studies (TWASs) of COVID-19 hospitalization/susceptibility and long COVID GWASs across 48 GTEx tissues

Evaluate genes adjacent to these candidate SNPs in phenotype-wide transcription association studies (Pheno-TWASs) across 48 GTEx tissues, covering a broad set of 420 phenotypes

Figure 2

Figure 3

Figure 4

Figure S1

Figure S2

Figure S3

Figure S4

Figure S5

Figure S6

Figure S7

Figure S8

Long COVID association signals for SNPs in the SNP category "Severe COVID-19-Specific SNPs"

Figure S9

Figure S10

Figure S11

Figure S12

Figure S13

Figure S14

Figure S15

Figure S16

Only combinations of genes and tissues with at least one TWAS association P < 0.01 are illustrated in the heatmap.

P<0.05   P<10⁻⁶

Figure S17

rs17219281..HLA-DQA2..BRD2......Brain Putamen basal ganglia..........
rs17219281..HLA-DQA2..BTNL2.....Nerve Tibial.......................
rs17219281..HLA-DQA2..C6orf10...Testis.............................
rs17219281..HLA-DQA2..COL11A2...Adrenal Gland......................
rs17219281..HLA-DQA2..COL11A2...Vagina.............................
rs17219281..HLA-DQA2..HLA-DMA...Heart Left Ventricle...............
rs17219281..HLA-DQA2..HLA-DMA...Liver..............................
rs17219281..HLA-DQA2..HLA-DMA...Skin Sun Exposed Lower leg.........
rs17219281..HLA-DQA2..HLA-DMB...Cells Transformed fibroblasts......
rs17219281..HLA-DQA2..HLA-DMB...Pancreas...........................
rs17219281..HLA-DQA2..HLA-DPA1..Testis.............................
rs17219281..HLA-DQA2..HLA-DPA1..Thyroid............................
rs17219281..HLA-DQA2..HLA-DPA1..Whole Blood........................
rs17219281..HLA-DQA2..HLA-DPB1..Brain Cerebellum...................
rs17219281..HLA-DQA2..HLA-DQA1..Adipose Visceral Omentum...........
rs17219281..HLA-DQA2..HLA-DQA1..Colon Transverse...................
rs17219281..HLA-DQA2..HLA-DQA1..Liver..............................
rs17219281..HLA-DQA2..HLA-DQA1..Muscle Skeletal....................
rs17219281..HLA-DQA2..HLA-DQA2..Brain Hippocampus..................
rs17219281..HLA-DQA2..HLA-DQA2..Colon Sigmoid......................
rs17219281..HLA-DQA2..HLA-DQA2..Pancreas...........................
rs17219281..HLA-DQA2..HLA-DQA2..Prostate...........................
rs17219281..HLA-DQA2..HLA-DQB1..Adipose Subcutaneous...............
rs17219281..HLA-DQA2..HLA-DQB1..Brain Anterior cingulate cortex BA24.
rs17219281..HLA-DQA2..HLA-DQB1..Muscle Skeletal....................
rs17219281..HLA-DQA2..HLA-DQB1..Pancreas...........................
rs17219281..HLA-DQA2..HLA-DQB1..Prostate...........................
rs17219281..HLA-DQA2..HLA-DQB1..Small Intestine Terminal Ileum.......
rs17219281..HLA-DQA2..HLA-DQB2..Artery Aorta.......................
rs17219281..HLA-DQA2..HLA-DQB2..Cells EBV-transformed lymphocytes....
rs17219281..HLA-DQA2..HLA-DQB2..Heart Atrial Appendage.............
rs17219281..HLA-DQA2..HLA-DQB2..Small Intestine Terminal Ileum.......
rs17219281..HLA-DQA2..HLA-DQB2..Testis.............................
rs17219281..HLA-DQA2..HLA-DRA...Thyroid............................
rs17219281..HLA-DQA2..HLA-DRB1..Brain Anterior cingulate cortex BA24.
rs17219281..HLA-DQA2..HLA-DRB1..Muscle Skeletal....................
rs17219281..HLA-DQA2..HLA-DRB1..Ovary..............................
rs17219281..HLA-DQA2..HLA-DRB1..Whole Blood........................
rs17219281..HLA-DQA2..HLA-DRB5..Adipose Subcutaneous...............
rs17219281..HLA-DQA2..NOTCH4....Adipose Visceral Omentum...........
rs17219281..HLA-DQA2..PSMB8.....Ovary..............................
rs17219281..HLA-DQA2..PSMB8.....Stomach............................
rs17219281..HLA-DQA2..PSMB9.....Adipose Visceral Omentum...........
rs17219281..HLA-DQA2..TAP1......Cells EBV-transformed lymphocytes....
rs17219281..HLA-DQA2..TAP1......Testis.............................
rs17219281..HLA-DQA2..TAP2......Skin Not Sun Exposed Suprapubic......
rs17219281..HLA-DQA2..TAP2......Skin Sun Exposed Lower leg.........
rs17219281..HLA-DQA2..TAP2......Testis.............................

$P < 1 \times 10^{-60}$

UKB Malabsorption or coeliac disease
RA OKADA TRANS ETHNIC
RA OKADA EUR
IMMUNOBASE Systemic lupus erythematosus hg19
RA OKADA ASIAN
UKB Hypothyroidism or myxoedema
UKB Asthma
IMMUNOBASE Multiple sclerosis hg19
RA GWASmeta2 20090505

Figure S18

rs9260038..HLA-A..GABBR1...Adipose Subcutaneous..................
rs9260038..HLA-A..GABBR1...Breast Mammary Tissue................
rs9260038..HLA-A..GABBR1...Nerve Tibial..........................
rs9260038..HLA-A..HLA-A....Esophagus Mucosa......................
rs9260038..HLA-A..HLA-A....Ovary.................................
rs9260038..HLA-A..HLA-A....Skin Not Sun Exposed Suprapubic.......
rs9260038..HLA-A..HLA-A....Skin Sun Exposed Lower leg............
rs9260038..HLA-A..HLA-A....Whole Blood...........................
rs9260038..HLA-A..HLA-F....Brain Cerebellar Hemisphere...........
rs9260038..HLA-A..HLA-F....Brain Cerebellum......................
rs9260038..HLA-A..HLA-F....Colon Sigmoid.........................
rs9260038..HLA-A..HLA-F....Esophagus Gastroesophageal Junction...
rs9260038..HLA-A..HLA-F....Liver.................................
rs9260038..HLA-A..HLA-F....Ovary.................................
rs9260038..HLA-A..HLA-F....Pancreas..............................
rs9260038..HLA-A..HLA-G....Brain Cerebellar Hemisphere...........
rs9260038..HLA-A..HLA-G....Brain Cortex..........................
rs9260038..HLA-A..HLA-G....Colon Transverse......................
rs9260038..HLA-A..HLA-G....Lung..................................
rs9260038..HLA-A..HLA-G....Testis................................
rs9260038..HLA-A..MAS1L...Stomach................................
rs9260038..HLA-A..MOG.....Artery Tibial..........................
rs9260038..HLA-A..MOG.....Esophagus Gastroesophageal Junction...
rs9260038..HLA-A..MOG.....Heart Left Ventricle...................
rs9260038..HLA-A..OR2H2....Adipose Subcutaneous..................
rs9260038..HLA-A..OR2H2....Heart Left Ventricle..................
rs9260038..HLA-A..OR2H2....Nerve Tibial..........................
rs9260038..HLA-A..OR2H2....Skin Sun Exposed Lower leg............
rs9260038..HLA-A..PPP1R11..Brain Cerebellum......................
rs9260038..HLA-A..PPP1R11..Cells Transformed fibroblasts.........
rs9260038..HLA-A..PPP1R11..Whole Blood...........................
rs9260038..HLA-A..RNF39....Brain Hippocampus.....................
rs9260038..HLA-A..RNF39....Brain Nucleus accumbens basal ganglia.
rs9260038..HLA-A..RNF39....Lung..................................
rs9260038..HLA-A..RNF39....Stomach...............................
rs9260038..HLA-A..TRIM10...Skin Sun Exposed Lower leg............
rs9260038..HLA-A..TRIM15...Colon Transverse......................
rs9260038..HLA-A..TRIM15...Skin Sun Exposed Lower leg............
rs9260038..HLA-A..TRIM26...Adipose Visceral Omentum..............
rs9260038..HLA-A..TRIM26...Artery Tibial.........................
rs9260038..HLA-A..TRIM26...Brain Caudate basal ganglia...........
rs9260038..HLA-A..TRIM26...Brain Cerebellum......................
rs9260038..HLA-A..TRIM26...Nerve Tibial..........................
rs9260038..HLA-A..TRIM26...Testis................................
rs9260038..HLA-A..TRIM31...Adrenal Gland.........................
rs9260038..HLA-A..TRIM31...Lung..................................
rs9260038..HLA-A..TRIM31...Pancreas..............................
rs9260038..HLA-A..TRIM31...Testis................................
rs9260038..HLA-A..TRIM39...Adipose Subcutaneous..................
rs9260038..HLA-A..TRIM39...Adrenal Gland.........................
rs9260038..HLA-A..TRIM39...Esophagus Mucosa......................
rs9260038..HLA-A..TRIM39...Nerve Tibial..........................
rs9260038..HLA-A..TRIM40...Testis................................
rs9260038..HLA-A..ZFP57....Heart Atrial Appendage................
rs9260038..HLA-A..ZFP57....Prostate..............................
rs9260038..HLA-A..ZFP57....Spleen................................
rs9260038..HLA-A..ZNRD1....Artery Tibial.........................
rs9260038..HLA-A..ZNRD1....Esophagus Gastroesophageal Junction...
rs9260038..HLA-A..ZNRD1....Thyroid...............................
rs9260038..HLA-A..ZNRD1....Whole Blood...........................

Column labels (bottom, left to right):
IMMUNOBASE Multiple sclerosis hg19
UKB Psoriasis
IMMUNOBASE Systemic lupus erythematosus hg19
RA OKADA ASIAN
UKB Diastolic blood pressure automated reading
MAGIC Manning et al FastingGlucose Interaction
UKB Waist circumference
UKB Sitting height
pgc.scz2
UKB Ankylosing spondylitis
UKB Sarcoidosis
UKB Hypothyroidism or myxoedema
UKB Hyperthyroidism aka thyrotoxicosis
UKB Standing height
RA GWASmeta2 20090505
RA OKADA EUR
RA OKADA TRANS ETHNIC
UKB Malabsorption or coeliac disease

$P < 1 \times 10^{-60}$

Figure S19

rs1634761..HLA-C..ABHD16A...Cells EBV-transformed lymphocytes.....
rs1634761..HLA-C..ABHD16A...Nerve Tibial........................
rs1634761..HLA-C..AIF1......Breast Mammary Tissue................
rs1634761..HLA-C..APOM......Prostate.............................
rs1634761..HLA-C..APOM......Stomach..............................
rs1634761..HLA-C..APOM......Testis...............................
rs1634761..HLA-C..BAG6......Brain Cortex.........................
rs1634761..HLA-C..BAG6......Brain Frontal Cortex BA9.............
rs1634761..HLA-C..BAG6......Brain Hypothalamus...................
rs1634761..HLA-C..C6orf15...Skin Sun Exposed Lower leg...........
rs1634761..HLA-C..C6orf25...Breast Mammary Tissue................
rs1634761..HLA-C..C6orf47...Thyroid..............................
rs1634761..HLA-C..CCHCR1....Artery Aorta.........................
rs1634761..HLA-C..CCHCR1....Brain Cerebellar Hemisphere..........
rs1634761..HLA-C..CLIC1.....Brain Cortex.........................
rs1634761..HLA-C..CLIC1.....Liver................................
rs1634761..HLA-C..CLIC1.....Spleen...............................
rs1634761..HLA-C..CSNK2B....Brain Nucleus accumbens basal ganglia.
rs1634761..HLA-C..CSNK2B....Stomach..............................
rs1634761..HLA-C..DDAH2.....Brain Cerebellum.....................
rs1634761..HLA-C..DDAH2.....Brain Frontal Cortex BA9.............
rs1634761..HLA-C..DDR1......Prostate.............................
rs1634761..HLA-C..DDX39B....Brain Anterior cingulate cortex BA24..
rs1634761..HLA-C..GPANK1....Adipose Subcutaneous.................
rs1634761..HLA-C..GPANK1....Muscle Skeletal......................
rs1634761..HLA-C..HCG27.....Skin Sun Exposed Lower leg...........
rs1634761..HLA-C..HCG27.....Testis...............................
rs1634761..HLA-C..HLA-B.....Pancreas.............................
rs1634761..HLA-C..HLA-C.....Spleen...............................
rs1634761..HLA-C..LSM2......Artery Aorta.........................
rs1634761..HLA-C..LST1......Brain Hypothalamus...................
rs1634761..HLA-C..LST1......Cells EBV-transformed lymphocytes.....
rs1634761..HLA-C..LTB.......Esophagus Gastroesophageal Junction...
rs1634761..HLA-C..LY6G5C....Adipose Visceral Omentum.............
rs1634761..HLA-C..LY6G6C....Brain Nucleus accumbens basal ganglia.
rs1634761..HLA-C..LY6G6C....Testis...............................
rs1634761..HLA-C..LY6G6D....Brain Anterior cingulate cortex BA24..
rs1634761..HLA-C..LY6G6F....Esophagus Mucosa.....................
rs1634761..HLA-C..LY6G6F....Testis...............................
rs1634761..HLA-C..MICA......Brain Putamen basal ganglia..........
rs1634761..HLA-C..MICA......Prostate.............................
rs1634761..HLA-C..MICA......Stomach..............................
rs1634761..HLA-C..MICB......Artery Aorta.........................
rs1634761..HLA-C..MICB......Spleen...............................
rs1634761..HLA-C..MSH5......Testis...............................
rs1634761..HLA-C..MUC21.....Brain Cerebellum.....................
rs1634761..HLA-C..MUC22.....Esophagus Mucosa.....................
rs1634761..HLA-C..NFKBIL1...Brain Cerebellum.....................
rs1634761..HLA-C..POU5F1....Stomach..............................
rs1634761..HLA-C..POU5F1....Whole Blood..........................
rs1634761..HLA-C..PRRC2A....Whole Blood..........................
rs1634761..HLA-C..PSORS1C1..Brain Cortex.........................
rs1634761..HLA-C..PSORS1C2..Vagina...............................
rs1634761..HLA-C..TCF19.....Colon Transverse.....................
rs1634761..HLA-C..TCF19.....Prostate.............................
rs1634761..HLA-C..TNF.......Brain Nucleus accumbens basal ganglia.
rs1634761..HLA-C..VARS2.....Brain Frontal Cortex BA9.............
rs1634761..HLA-C..VARS2.....Lung.................................
rs1634761..HLA-C..VARS2.....Pancreas.............................
rs1634761..HLA-C..VARS......Vagina...............................
rs1634761..HLA-C..VWA7......Nerve Tibial.........................

Column labels:
IMMUNOBASE Multiple sclerosis hg19
RA GWASmeta2 20090505
UKB Basal metabolic rate
UKB Asthma
UKB Hypothyroidism or myxoedema
RA OKADA ASIAN
AdvancedAMD 2015
UKB Hyperthyroidism aka thyrotoxicosis
UKB Ankylosing spondylitis
RA OKADA EUR
RA OKADA TRANS ETHNIC
IMMUNOBASE Systemic lupus erythematosus hg19
UKB Malabsorption or coeliac disease

$P < 1 \times 10^{-60}$

Figure S20

Figure S21

rs9916158..GSDMA/B..CASC3.....Brain Cortex.................................
rs9916158..GSDMA/B..CASC3.....Brain Nucleus accumbens basal ganglia.
rs9916158..GSDMA/B..CASC3.....Esophagus Mucosa........................
rs9916158..GSDMA/B..CASC3.....Prostate..................................
rs9916158..GSDMA/B..CASC3.....Testis....................................
rs9916158..GSDMA/B..CASC3.....Thyroid...................................
rs9916158..GSDMA/B..CDC6.....Artery Aorta.............................
rs9916158..GSDMA/B..CDC6.....Thyroid..................................
rs9916158..GSDMA/B..CSF3.....Brain Cerebellum.........................
rs9916158..GSDMA/B..CSF3.....Nerve Tibial.............................
rs9916158..GSDMA/B..CSF3.....Spleen...................................
rs9916158..GSDMA/B..ERBB2.....Brain Anterior cingulate cortex BA24..
rs9916158..GSDMA/B..ERBB2.....Heart Atrial Appendage..................
rs9916158..GSDMA/B..ERBB2.....Nerve Tibial............................
rs9916158..GSDMA/B..ERBB2.....Testis..................................
rs9916158..GSDMA/B..GRB7.....Brain Cerebellar Hemisphere.............
rs9916158..GSDMA/B..GRB7.....Skin Sun Exposed Lower leg..............
rs9916158..GSDMA/B..GRB7.....Stomach.................................
rs9916158..GSDMA/B..GRB7.....Uterus..................................
rs9916158..GSDMA/B..GSDMA.....Adipose Visceral Omentum...............
rs9916158..GSDMA/B..GSDMA.....Cells Transformed fibroblasts..........
rs9916158..GSDMA/B..GSDMA.....Esophagus Gastroesophageal Junction...
rs9916158..GSDMA/B..GSDMA.....Muscle Skeletal........................
rs9916158..GSDMA/B..GSDMA.....Small Intestine Terminal Ileum........
rs9916158..GSDMA/B..GSDMA.....Thyroid................................
rs9916158..GSDMA/B..GSDMA.....Whole Blood............................
rs9916158..GSDMA/B..GSDMB.....Colon Transverse.......................
rs9916158..GSDMA/B..GSDMB.....Small Intestine Terminal Ileum........
rs9916158..GSDMA/B..GSDMB.....Spleen.................................
rs9916158..GSDMA/B..GSDMB.....Stomach................................
rs9916158..GSDMA/B..GSDMB.....Whole Blood............................
rs9916158..GSDMA/B..IGFBP4.....Cells Transformed fibroblasts.........
rs9916158..GSDMA/B..IGFBP4.....Heart Left Ventricle.................
rs9916158..GSDMA/B..IGFBP4.....Spleen...............................
rs9916158..GSDMA/B..IGFBP4.....Thyroid..............................
rs9916158..GSDMA/B..IKZF3.....Whole Blood...........................
rs9916158..GSDMA/B..LRRC3C.....Skin Sun Exposed Lower leg...........
rs9916158..GSDMA/B..LRRC3C.....Thyroid..............................
rs9916158..GSDMA/B..MED24.....Brain Caudate basal ganglia..........
rs9916158..GSDMA/B..MED24.....Brain Cortex.........................
rs9916158..GSDMA/B..MED24.....Brain Frontal Cortex BA9.............
rs9916158..GSDMA/B..MED24.....Brain Hypothalamus...................
rs9916158..GSDMA/B..MED24.....Spleen...............................
rs9916158..GSDMA/B..MED24.....Whole Blood..........................
rs9916158..GSDMA/B..MIEN1.....Cells Transformed fibroblasts........
rs9916158..GSDMA/B..MIEN1.....Heart Left Ventricle.................
rs9916158..GSDMA/B..MIEN1.....Skin Sun Exposed Lower leg...........
rs9916158..GSDMA/B..MIEN1.....Spleen...............................
rs9916158..GSDMA/B..MIEN1.....Testis...............................
rs9916158..GSDMA/B..MSL1.....Artery Aorta..........................
rs9916158..GSDMA/B..MSL1.....Brain Cortex..........................
rs9916158..GSDMA/B..MSL1.....Spleen................................
rs9916158..GSDMA/B..MSL1.....Testis................................
rs9916158..GSDMA/B..NEUROD2.....Testis..............................
rs9916158..GSDMA/B..NR1D1.....Skin Sun Exposed Lower leg...........
rs9916158..GSDMA/B..ORMDL3.....Cells EBV-transformed lymphocytes.....
rs9916158..GSDMA/B..ORMDL3.....Lung.................................
rs9916158..GSDMA/B..ORMDL3.....Uterus...............................
rs9916158..GSDMA/B..ORMDL3.....Vagina...............................
rs9916158..GSDMA/B..ORMDL3.....Whole Blood..........................
rs9916158..GSDMA/B..PGAP3.....Esophagus Mucosa......................
rs9916158..GSDMA/B..PGAP3.....Esophagus Muscularis..................
rs9916158..GSDMA/B..PGAP3.....Heart Left Ventricle..................
rs9916158..GSDMA/B..PGAP3.....Liver.................................
rs9916158..GSDMA/B..PGAP3.....Lung..................................
rs9916158..GSDMA/B..PGAP3.....Skin Not Sun Exposed Suprapubic.......
rs9916158..GSDMA/B..PGAP3.....Thyroid...............................
rs9916158..GSDMA/B..PNMT.....Artery Tibial..........................
rs9916158..GSDMA/B..PNMT.....Brain Cerebellar Hemisphere............
rs9916158..GSDMA/B..PNMT.....Heart Atrial Appendage.................
rs9916158..GSDMA/B..PNMT.....Nerve Tibial...........................
rs9916158..GSDMA/B..PPP1R1B...Adipose Subcutaneous...................
rs9916158..GSDMA/B..PPP1R1B...Esophagus Mucosa......................
rs9916158..GSDMA/B..PPP1R1B...Heart Atrial Appendage.................
rs9916158..GSDMA/B..PPP1R1B...Prostate..............................
rs9916158..GSDMA/B..PSMD3.....Brain Cerebellar Hemisphere...........
rs9916158..GSDMA/B..PSMD3.....Cells Transformed fibroblasts.........
rs9916158..GSDMA/B..PSMD3.....Esophagus Mucosa......................
rs9916158..GSDMA/B..PSMD3.....Heart Left Ventricle..................
rs9916158..GSDMA/B..PSMD3.....Ovary.................................
rs9916158..GSDMA/B..PSMD3.....Spleen................................
rs9916158..GSDMA/B..RAPGEFL1..Brain Putamen basal ganglia...........
rs9916158..GSDMA/B..RAPGEFL1..Cells EBV-transformed lymphocytes.....
rs9916158..GSDMA/B..RAPGEFL1..Small Intestine Terminal Ileum........
rs9916158..GSDMA/B..RAPGEFL1..Stomach...............................
rs9916158..GSDMA/B..RAPGEFL1..Testis................................
rs9916158..GSDMA/B..RAPGEFL1..Thyroid...............................
rs9916158..GSDMA/B..RAPGEFL1..Whole Blood...........................
rs9916158..GSDMA/B..RARA.....Brain Hippocampus......................
rs9916158..GSDMA/B..RARA.....Brain Nucleus accumbens basal ganglia.
rs9916158..GSDMA/B..RARA.....Pancreas...............................
rs9916158..GSDMA/B..RARA.....Whole Blood............................
rs9916158..GSDMA/B..STARD3...Cells Transformed fibroblasts.........
rs9916158..GSDMA/B..STARD3...Skin Not Sun Exposed Suprapubic.......
rs9916158..GSDMA/B..STARD3...Stomach...............................
rs9916158..GSDMA/B..TCAP.....Breast Mammary Tissue..................
rs9916158..GSDMA/B..THRA.....Adipose Subcutaneous...................
rs9916158..GSDMA/B..THRA.....Artery Tibial..........................
rs9916158..GSDMA/B..THRA.....Esophagus Mucosa.......................
rs9916158..GSDMA/B..THRA.....Muscle Skeletal........................
rs9916158..GSDMA/B..THRA.....Skin Sun Exposed Lower leg.............
rs9916158..GSDMA/B..THRA.....Whole Blood............................
rs9916158..GSDMA/B..TNS4.....Skin Sun Exposed Lower leg.............
rs9916158..GSDMA/B..TOP2A....Cells Transformed fibroblasts.........
rs9916158..GSDMA/B..TOP2A....Colon Sigmoid.........................
rs9916158..GSDMA/B..TOP2A....Lung..................................
rs9916158..GSDMA/B..TOP2A....Spleen................................
rs9916158..GSDMA/B..TOP2A....Uterus................................
rs9916158..GSDMA/B..TOP2A....Whole Blood...........................
rs9916158..GSDMA/B..WIPF2....Adrenal Gland.........................
rs9916158..GSDMA/B..WIPF2....Brain Cerebellum......................
rs9916158..GSDMA/B..WIPF2....Esophagus Mucosa......................
rs9916158..GSDMA/B..ZPBP2....Testis................................

$P < 0.05$

$P > 0.05$ $P < 1 \times 10^{-6}$

Figure S22

Figure S23

Figure S24